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Human red blood cells (RBCs) provide essential gaseous exchanges to all body’s tissues and
organs through the circulatory system. RBCs lack of nucleus and organelles provides as much
room as possible for the oxygen-carrying protein hemoglobin. Hemoglobin composes ~98% of
the soluble proteins in mature RBCs. RBCs have a biconcave shape corresponding to a large
cellular surface area-to-volume ratio allowing for efficient gas exchange and increased cell
deformability ensuring passage through the narrowest capillaries without rupturing and vessel
obstruction. In sickle cell disease (SCD), a single point mutation occurs in the beta-globin gene,
resulting in the production of abnormal hemoglobin (HbS) which, in deoxygenated conditions,
polymerizes to form stiff filaments deforming SCD RBCs (SS-RBCs) to a wide variety of sickle
shapes. In addition to the irregular shape, SS-RBCs are stiffer, more viscous, and show higher
adhesion than normal (wild-type) WT-RBCs to other RBCs, platelets, leukocytes, and to the
endothelium. Consequently, abnormal SS-RBC adhesion leads to delayed microvascular
passage of deoxygenated RBCs inducing sickling and entrapment of RBCs, a key trigger of vasoocclusive episodes (VOEs) which is the pathophysiologic hallmark of SCD.

We employed a powerful technique called single-molecule force spectroscopy to investigate the
mechanism of RBC adhesion and signaling, and to guide advances in SCD pharmacotherapy.
Specifically, we studied the effect of the cyclic adenosine monophosphate-protein kinase A
(cAMP-PKA) dependent signaling pathway on the activation of intercellular adhesion molecule-4
(ICAM-4) receptors, which express on the RBC surface and bind with high-affinity to endothelial
αvβ3 integrin, in turn, inducing endothelial injury and inflammation likely contributing to VOEs in
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SCD. We demonstrated that the activation of ICAM-4 receptors is regulated via the cAMP-PKA
pathway and importantly we determined for the first time that this activation is mediated by Akinase anchoring proteins (AKAPs). We also investigated the possibility of receptor cross-talk
between the β-adrenergic receptor (β-AR) and the angiotensin II type 1 receptor (AT1R), which
resulted in a trans-inhibitory effect of valsartan on the ICAM-4 activation. These findings may lead
to novel pharmacological approaches for the prevention and treatment of VOEs.
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Chapter 1. Introduction

1.1. Human erythrocytes

Red blood cells (RBCs), also known as red cells, erythroid cells or erythrocytes are the most
common type of blood cell and provide essential gaseous (O2, CO2) exchanges to tissues and
organs ensuring them to sustain their normal functions (1-4). RBCs were also considered for a
long time as a scavenger of endothelial cell-derived nitric oxide (NO), modulating the balance
between NO formation and inhibition (5), participating in systemic NO metabolism (6, 7). RBCs
were first observed and described by a Dutch biologist and microscopist, Jan Swammerdam in
1668. Later in 1675 another Dutch microscopist, Antonie van Leeuwenhoek, first published a
remarkable description of the unique features of human RBCs, which stated in a healthy body
RBCs should be soft and flexible, that they may be capable of passing through the capillaries, by
easily changing their round shapes into ovals, and also reassuming their former roundness when
they come into larger vessels (8-10). All blood cells, including erythrocytes, leukocytes and
platelets, arise from the same bone marrow stem cells that acquire their unique characteristics
after undergoing a process of specialization (11-15). In humans, RBCs develop in the bone
marrow from haematopoietic stem and progenitor cells (HSPCs) via a complex maturation
cascade known as erythropoiesis and live for about 120 days (16-20). The formation of RBCs is
a dramatic process due to purging most of the organelles, such as nucleus, mitochondria,
ribosomes and more, in order to make as much room as possible for the oxygen-carrying protein
hemoglobin. Towards the end of erythropoiesis, immature red blood cells also known as
reticulocytes (multi-lobular and spherical) experience dynamic re-arrangements to yield highly
deformable biconcave erythrocytes (normocytes), which nourish the body with oxygen through
the circulatory system (16, 21-23). In the rapid transition of reticulocyte to RBC, UBE20, an E2-
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E3 hybrid enzyme, serve as the main drive. UBE20 recognizes and ubiquitinates myriad proteins
that are fated for elimination. The target proteins are then degraded by the proteasome and
ubiquitin is recycled (24). Eventually, RBCs take the form of flexible biconcave disks that lack a
cell nucleus and organelles and they cannot synthesize protein. The molecular mechanisms
underpinning these remarkable morphological and bio-mechanical transformations were deeply
studied through quantitative profiling of protein composition and imaging (16) and quantitative
mass spectrometry techniques (16, 24). In the mature RBCs, hemoglobin composes ~98% of the
soluble proteins (24). RBCs take up oxygen in the lungs through binding to hemoglobin and
release it while flowing through the body's circulatory system. The blood's red color is due to the
color of oxygen-rich hemoglobin (25-27).

The biconcave shape of the human RBCs is fundamental for their physiological function as it
increases overall cell deformability and creates a high cellular surface area-to-volume ratio
allowing for efficient gas exchange (1, 28-31). It can be critically affected by genetic or acquired
pathological conditions (1, 28). To deliver oxygen to the tissues, RBCs must be able to
dynamically adapt to and compensate for the constantly changing flow conditions along the
vascular tree and particularly in the narrowest capillaries to deform significantly without rupturing
and obstructing the vessels (32).

Equivalently important is that RBCs express more than 50 transmembrane proteins of various
abundance ranging from a few hundred to a million copies. These membrane proteins exhibit
diverse functional heterogeneity, serving as transport proteins, as signaling receptors, and as
adhesion proteins involved in the interactions of RBCs with other blood cells and endothelial cells
(33-38). Adhesion molecules mediate intercellular adhesion mechanisms and interactions with
proteins of the extracellular matrix (39-42). Adhesion molecules carrying blood group antigens
(like CD44, Lu, LW, CD47, and CD147) are involved in the pathophysiology of malaria, sickle cell
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disease (SCD) and diabetes, as well as in thrombosis, mainly through an abnormal adhesion to
the vascular endothelium (43-49). Meanwhile, adhesion molecules on RBCs might also interact
with the developing thrombus, for instance through interaction with cells expressing integrins,
such as activated leukocytes, monocytes and platelets (44, 50).

1.2. Sickle cell disease and sickle cell trait

Sickle cell disease (SCD) was first described by the Chicago physician, Dr. James B Herrick in
1910 (51-54). In the blood examination of a young African descent patient, there were a large
number of thin, elongated, sickle-shaped and crescent-shaped red corpuscles. These peculiar
elongated forms of the red corpuscles were never saw and no conclusions could be drawn from
the case at the time (52). It was almost 4 decades later that Linus Pauling and his
colleagues revealed that SCD was caused by a genetic disorder (55). SCD is a group of blood
disorders that result from a recessively inherited point mutation occurring in the β-globin gene and
lead to altered membrane and cell functions (56-58). The point mutation replaces A with T at
codon 6 of beta hemoglobin chain (59). This causes the switch of protein production from glutamic
acid (charged) to valine amino acid (hydrophobic) at the beta 6 site and gives rise to abnormal
(sickle) hemoglobin (HbS). The valine-type hemoglobin polymerizes to form stiff filaments when
exposed to low oxygen conditions (60-62), causing a distortion in the shape of the RBCs from
biconcave to sickled. Because of their distorted shape, RBCs carrying the defective hemoglobin
HbS are called sickle RBCs (SS-RBCs). In addition to their irregular shape, compared with normal
(wild-type, WT) RBCs, SS-RBCs are stiffer and more viscous, and show higher adhesion to other
RBCs, platelets, leukocytes, and the endothelium (43, 44, 61, 63-67). In SCD, an abnormally high
expression of α4β1 (VLA-4, fibronectin receptor), CD36 (thrombospondin receptor) and adhesion
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molecules like BCAM(Lu, CD239) and ICAM-4 (LW, CD242) on the RBC surface contributes
largely to their adhesion to the activated endothelium surface, thus leading to a decreased blood
flow and delayed microvascular passage of deoxygenated RBCs, inducing sickling and
entrapment of RBCs, sequentially, to occurrence of serious vaso-occlusive problems which are
among the major clinical complications (painful crisis, acute chest syndrome, infections, strokes)
in this disease (68-74).

As the key adhesion molecule mediating the adhesion between RBCs and endothelium, LW
antigens reside on a 42-kDa red cell membrane glycoprotein named CD242, encoded by a gene
located on chromosome 19 (75, 76). The LW glycoprotein was renamed ICAM-4 based on strong
sequence similarities with the intercellular adhesion molecule (ICAM) family, a group of molecules
that play a crucial role in cell-cell interactions (77-79). In SCD, abnormal adhesion of RBCs to
endothelial cells is primarily mediated by the intercellular adhesion molecule -4 (ICAM-4) which
expresses on the RBC membrane and binds to the endothelial αvβ3 integrin (80-82). This is a
key factor in triggering vaso-occlusive episodes (VOEs), the hallmark of SCD. Better
understanding of the mechanisms that control RBC adhesion to the endothelial cells may lead to
novel approaches for both prevention and treatment of VOEs in SCD. One important mechanism
of ICAM-4 activation is via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA)
dependent signaling pathway (83-86).

In homozygous SCD, irreversibly sickled red cells are seen in routine peripheral blood smears
(87-89). From its onset, the disease runs an unremitting course punctuated by sudden crises.
Homozygous SCD usually is asymptomatic until 6 months of age when the shift from HbF to HbS
is complete. The anemia is moderate to severe; most patients have hematocrits of 18% to 30%
(normal range, 38% to 48%) (90). In addition to these crises, patients with SCD are prone to
infections. Both children and adults with SCD are functionally asplenic, making them susceptible
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to infections caused by encapsulated bacteria, such as pneumococci. There are also common
complications, such as pulmonary hypertension, acute chest syndrome, stroke, unhealing leg
ulcers, and eye damage (91).

The clinical course of SCD is highly variable (92). As a result of improvements in supportive care,
an increasing number of patients are surviving into adulthood. Approximately 50% of patients now
survive beyond the fifth decade (93). Current Treatment involves a number of measures. A
mainstay of therapy is hydroxyurea, so far the only FDA-approved drug to treat SCD. Hydroxyurea
reduces pain crises and lessens the anemia through several effects, including 1) an increase in
levels of HbF; 2) an anti-inflammatory effect because of the inhibition of white cell production; 3)
an increase in RBC size, which lowers the intracellular hemoglobin concentration; and 4) its
metabolism to NO, a potent vasodilator and inhibitor of platelet aggregation (94-100). However,
only two-thirds of patients respond favorably to the drug. There are pain medications for various
pain levels. Antibiotics such as penicillin and routine vaccinations are used to prevent infections
in babies and young children. Blood transfusions are widely used to treat worsening anemia and
sickle cell complications. Encouraging results also have been obtained with allogeneic bone
marrow transplantation, which is potentially curative. But due to its significant risks, transplants
are not appropriate for every patient (101-104). Lately, anti-adhesive therapies have drawn much
attention due to the possibility of attenuating vaso-occlusion. New medicines have shown positive
results on pre-clinical data and clinical trials (105-114).

Sickle cell trait (SCT) is a heterozygous state characterized by the presence of both normal
hemoglobin (HbA) and HbS (115-117). Patient with sickle cell trait receives HbS from one parent
and HbA from the other parent. While patients with SCD suffer increased mortality and often
widespread chronic organ damage, individuals with SCT are generally asymptomatic and live a
normal lifespan (118). However, under extreme conditions, such as hypoxia, acidosis, and
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dehydration, individuals with SCT can develop a syndrome resembling SCD with vaso-occlusive
sequelae (119-122).

As of 2015, about 4.4 million people have sickle cell disease worldwide, while 404 million have
sickle cell trait (123, 124). Painful vaso-occlusive crises are often treated symptomatically with
pain medications rather than treat the underlying cause; pain management requires opioid
administration at regular intervals until the crisis has settled. This has contributed significantly to
the low quality of life endured by those that live with this disease (125). It is estimated in the U.S.
alone that there are ~200,000 emergency department presentations annually for VOE pain (126).
These acute care costs approximate $1 billion a year (127). Clearly, there are both patientcentered and societal reasons requiring further research in this area.

One of the limitations of current research is that while it is known that VOEs are at least in part
due to interactions between RBCs and the endothelium via receptor-ligand including BCAM/Lulaminin (128) and ICAM-4-αvβ3 (129), the quantitative understanding of this biomechanical
process is limited. It is not known how the expression of functionally active adhesion receptors
varies (1) between individuals with SCD and (2) during the onset of VOE.

1.3. AFM biomedical techniques and applications

Atomic Force Microscopy (AFM) is a type of high-resolution scanning probe microscopy that
allows for imaging, manipulation and force measurement (130-135). It is a widely used and
powerful technique for investigating materials at a nanoscale range. AFM was invented in 1986
by Binnig, Quate, and Gerber as a way of overcoming the drawbacks of scanning tunneling
microscopy (STM) (136). It is used in a variety of different scientific areas, including solid-state
6

physics, semiconductor science, molecular engineering, polymer and surface chemistry,
molecular biology, cell biology, and medicine (137-141).

An AFM uses a cantilever with a tiny sharp tip at the end to scan over a sample surface. It uses
various forces that develop when two objects are brought within nanometers of each other.
Typically, an AFM can work either when the probe is in contact with a surface, causing a repulsive
force, or when it is a few nanometers away, where the force is attractive. As the tip lowers to the
surface, the close-range attractive forces between the surface and the tip make the cantilever to
bend towards the surface. However, as the cantilever is brought even closer to the surface
increasingly repulsive forces cause the cantilever to bend away from the surface (142-144). An
AFM has a Z-scanner (piezo) that moves the cantilever up and down, an XY-scanner (piezo) that
moves the sample back and forth underneath the cantilever and a position detector (PD) that
records the bending of the cantilever. The position sensor works by tracking a laser beam that is
reflected off the flat top, see Figure 1.1A (145).
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A

B

Figure 1.1. The principle of AFM (145). (A) Schematic of the main components of an AFM
device with working principles. (B) A schematic photodetector signal of the cantilever deflection
recorded during a single molecule force spectroscopy (SMFS) curve together with the
corresponding position of the cantilever and surface.

AFM is most commonly used to determine the topography of a surface, which is the foundation
of conventional AFM techniques, there is also a range of AFM variations, such as Kelvin Probe
8

Force Microscopy (KPFM, which is a technique that measures the potential difference between a
sample and the AFM tip) (146, 147), magnetic force microscopy (MFM, the tip detects the
magnetic interactions at the surface of the material and builds up a spatial distribution map of the
material’s magnetic structure) (148), and dual-probe AFM (DP-AFM, two independent probes
operating in a common workspace enabling two AFM operations to be carried out simultaneously)
(149-151).

AFM has become a widely used technique due to its high resolution especially to the molecular
level of biology samples (152). The increasing use of AFM in biology and medicine is a driving
factor of its rapid growth (153). Not only the surface topography of cells can be imaged by AFM
(154), but changes in the biophysical properties of the cell membrane such as cell stiffness and
adhesion can be measured as well (155-163). Samples can be directly analyzed in their natural
physiological conditions, without the need for any sample preparation, saving a lot of research
time.

Recent advances in AFM involve usage in cancer research and diagnosis (164, 165). AFM can
detect the changes and differences between single cancerous and non-cancerous cells, which
can allow for early diagnosis and treatment of cancer. AFM can also reveal the structure and
function of cancerous cells by identifying the mechanisms involved in their spreading and the
interaction processes between cells (166).

AFM is capable of testing the interactions of drugs with receptors as well as testing the contact of
the drug candidate with target cell membranes. Due to the non-destructive feature of AFM, it can
be used to look at soft samples under controlled environmental conditions, which then serves as
a unique foundation for the in vitro development of novel drug delivery systems. Enzyme
hydrolysis visualization can also be done by the phase imaging mode of the AFM which provides
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thorough qualitative and quantitative evaluation of pharmaceutical formulations. AFM is currently
the only available technique that is capable of measure forces in the pN range.

In this study, we utilized a MFP-3D-BIO AFM from Asylum Research (Figure 1.2). It is mounted
on top of an inverted microscope, which allowed visualization of the RBCs throughout
experiments. Two kinds of silicon nitride probe were used. One consisting of triangle cantilevers
which have tiny pyramid tips at the end (Figure 1.3), was used for the single molecule force
spectroscopy (SMFS, Figure 1.1B). The other has tipless triangle cantilevers (Figure 1.4) and was
used for the single cell force spectroscopy (SCFS, Figure 1.5).

Figure 1.2. MFP 3D-BIO AFM. Labeled components of the AFM atop a Zeiss optical inverted
microscope (167).
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Figure 1.3. AFM probe with triangle cantilevers and pyramid tips (168). (A) Schematic of
triangle cantilevers. (B) Schematic of a tip.

Figure 1.4. AFM probe with triangle tipless cantilevers (169).

Figure 1.5. Schematic of a single cell force spectroscopy (SCFS) experiment.
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SMFS

SMFS enables detection of single adhesion receptors on the RBC surface via measurement of
the unbinding events between receptors and the ligand protein attached to the tip of an AFM
cantilever, see Figure 1.1B.

SCFS

SCFS is capable of measuring adhesion of an entire cell to a protein- or cell-functionalized
substrate, see Figure 1.5. A single cell is captured by a tipless cantilever and relocated to the
protein- or cell-functionalized region where approaching and retracting force cycles are performed.

1.4. Objectives

The objectives for subsequent chapters are outlined as following.

Chapter 2. Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is
Revealed by AFM

The in vitro technique of single-molecule force spectroscopy was applied to investigate the effects
of subcellular cAMP-PKA signaling pathway and AKAPs on ICAM-4 receptor expression on
normal and SS-RBCs. Human normal and sickle RBCs adhere to endothelium largely through the
ICAM-4 receptor which is implicated in VOEs in SCD and activated through the cAMP signaling
pathway. We measured the unbinding force between ICAM-4 on the RBC and αvβ3 attached to
the AFM probe. We showed that the number of active ICAM-4 receptors on normal RBCs is not
significantly different from that of SS-RBCs. In addition, we showed that epinephrine, a
12

catecholamine that binds to the β-adrenergic receptor and activates the cAMP-PKA dependent
pathway, caused a significant increase in the frequency of active ICAM-4 receptors in both normal
and SS-RBCs. However, the unbinding force between ICAM-4 and the corresponding ligand αvβ3
remained the same. Furthermore, we demonstrated that forskolin (FSK), an adenylyl cyclase (AC)
activator, significantly increased the frequency of ICAM-4 receptors on normal and SS-RBCs
confirming that the activation of ICAM-4 is regulated by the cAMP-PKA pathway. Furthermore,
we illustrated that A-kinase anchoring proteins (AKAPs) play an essential role in ICAM-4
activation. The findings might be of clinical importance in the context of drug development for the
prevention and treatment of VOE in SCD.

Chapter 3. Valsartan Impedes Epinephrine-induced ICAM-4 Activation on Normal, Sickle Cell
Trait and Sickle Cell Disease Red Blood Cells

Abnormal RBC adhesion to endothelial αvβ3 plays a crucial role in triggering vaso-occlusive
episodes in SCD. It has been demonstrated that in human embryonic kidney 293 cells, mouse
cardiomyocytes, and COS-7 cell lines, the β-adrenergic and renin-angiotensin systems are
interrelated and that there is a direct interaction and cross-regulation between β-AR and
angiotensin II type 1 receptor (AT1R). Selective blockade of AT1R reciprocally inhibits the
downstream signaling of β-ARs. Similar to the inhibition observed in the presence of a β-ARblocker. We made a hypothesis that this mechanism is active in RBCs. Through SMFS, we
studied the effect of valsartan, an AT1R blocker, on the surface density of active ICAM-4 receptors
on normal, sickle cell trait, and homozygous sickle RBCs. We found that pretreatment of RBCs
with valsartan significantly impeded the activation of ICAM-4 receptors induced by epinephrine.
This trans-inhibitory effect of valsartan may lead to novel pharmacological approaches for the
prevention and treatment of vaso-occlusive crisis in SCD.
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Chapter 4. Influence of Clinical Chemotherapeutic Agents on the Activation of RBC ICAM-4
Adhesion Receptors Varies Due to Race and SCT Carrying Status

Clinical disparities have been observed between African-American and white females. AfricanAmericans experience higher rates of adverse events during chemotherapy, particularly among
breast cancer patients, they have more than 10% lower breast cancer survival than white females,
and this difference persisted over time. This suggests inherited host factors may contribute to
differential outcomes. An unstudied genetic trait in cancer outcomes are hemoglobinopathies,
particularly SCT which is estimated to occur in 8-10% of African-Americans. SMFS was employed
to detect the ICAM-4 expression on RBCs from three groups of participants: white female with
wild-type hemoglobin (WFWT), black female with wild-type hemoglobin (BFWT), and black female
sickle cell trait (BFSCT) with and without the administration of two chemotherapeutic agents,
cyclophosphamide (CYP) and daunorubicin (DNR). We found that both drugs did not affect the
ICAM-4 expression on WFWT-RBCs. CYP only significantly increased the ICAM-4 expression on
BFWT-RBCs. In contrast, DNR only increased significantly the ICAM-4 expression on BFSCTRBCs. The findings suggest race and SCT carrying status might be critical factors in choosing
chemotherapy drugs for different patients.

Chapter 5. Further Approaches to Understand RBC Biophysics

A cell is neither a perfect elastic solid nor a perfect viscous liquid. Thus, in addition to Young’s
modulus describing only the stiffness, a complex modulus consisting of both elastic and viscosity
modulus would be a more accurate indicator for the mechanical properties of cells. Here, more
attempts were made to further understand RBC biophysics. AFM generated time-dependent
loadings were applied to RBC membrane and the cell responses were recorded and analyzed.
The results indicated the complex modulus changes more rapidly in the high-frequency domain
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than in the low-frequency domain. Furthermore, hypoxia could significantly alter the RBC stiffness
and adhesion properties.

1.5. Rationale

RBC abnormal cytoadhesion is known to play a significant role in the genesis of vaso-occlusion
in SCD. In addition, the degree of RBC adhesion has been shown to correlate with clinical severity
of VOEs (65, 170). Studies using a variety of adhesion assays including micropipetting and
perfusion chambers revealed that SS-RBCs adhere to endothelial cells, progressively inducing
endothelial injury and inflammation contributing to vaso-occlusive events. ICAM-4 receptor on
RBC binding with high affinity specifically to endothelial integrin αvβ3 is a major mediator to RBC
cytoadhesion with endothelium. However, the mechanism underlying the abnormal adhesion is
not fully understood. The clinical management of SCD is still basic and in great need for
improvement, given the facts that only two-thirds of patients respond favorably to the only drug
Hydroxyurea, blood transfusion and bone marrow transplant limitedly apply to selective patients.
Therefore, substantial work is demanded to better understand and manage RBC cytoadhesion,
in an effort to develop better therapeutic methods for the prevention and treatment of VOEs.

ICAM-4 activation is mediated at least partially through the cAMP-PKA signaling pathway and
may involve in cross-talk between the β-adrenergic receptor (β-AR) and angiotensin type 1
receptor (AT1R). We employed an in vitro technique, single-molecule force spectroscopy (SMFS)
based on AFM, to study human normal, SCT-, and SCD-RBC adhesion in physiological conditions.
SMFS enables measurement of the unbinding force between ICAM-4 and αvβ3, the
intermolecular force in pN range. Most importantly, SMFS enables detection of single ICAM-4
molecules on the RBC surface, revealing the distribution and population of the active adhesion
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receptors with and without the presence of biomedical reagents. By studying RBC adhesion using
SMFS, we expect a significant impact on identifying potential targets and reagents for antiadhesive therapies to prevent and treat VOEs in SCD, providing supporting data for preclinical
researches and clinical trials.
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Chapter 2. Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs
via AKAPs Is Revealed by AFM

2.1. Introduction

Sickle cell disease (SCD) is a blood disorder due to a recessively inherited point mutation
occurring in the beta-globin gene, giving rise to abnormal hemoglobin (HbS) which, in
deoxygenated conditions, polymerizes to form stiff filaments (60-62). This causes distortion to the
shape of the RBC from biconcave to "sickled". Because of their distorted shape, RBCs carrying
the defective hemoglobin HbS are called sickle RBCs (SS-RBCs). In addition to the irregular
shape, SS-RBCs are stiffer, more viscous, and show higher adhesion than normal (wild-type) WTRBCs to other RBCs, platelets, leukocytes, and to the endothelium (61, 63-67). Abnormal SSRBC adhesion leads to delayed microvascular passage of deoxygenated RBCs inducing sickling
and entrapment of RBCs, a key trigger of vaso-occlusive episodes (VOEs) which are the
pathophysiologic hallmark of SCD (74). In addition, the degree of RBC adhesion has been shown
to correlate with clinical severity of VOEs (65, 170).

Work from others and us (74, 171, 172) has demonstrated that increased SS-RBC adhesion is
due to enhanced expression of functional adhesion receptors on the RBC membrane. RBC
receptor activation is dependent upon intracellular signaling pathways (5) that can be activated
by extracellular stimuli. One such pathway is cAMP-PKA which can be activated by epinephrine,
a catecholamine, which binds to G protein-coupled receptor (74, 172, 173). It has been shown
that the cAMP-PKA pathway directly regulates the activation of the basal cell adhesion
molecule/Lutheran (BCAM/Lu) on the RBC surface (172, 174). These BCAM/Lu receptors in turn
bind to laminin-alpha-5, a component of the endothelial subcellular matrix (174). In addition,
studies using a variety of adhesion assays including micropipetting and perfusion chambers
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revealed that SS-RBCs adhere to endothelial cells (170, 175), inducing endothelial injury and
inflammation likely contributing to vaso-occlusive events (65, 170, 176-178). Zennadi et al. (66)
further showed that intercellular adhesion molecule-4 (ICAM-4) was the primary receptor
mediating the adhesion of SS-RBCs to endothelial cells and that the ligand for the ICAM-4
receptor was the endothelial αvβ3 integrin (66, 179, 180). They also identified that epinephrine
can stimulate the activation of ICAM-4 at least partially via the cAMP-PKA dependent signaling
pathway. Specifically, epinephrine stimulates RBC β2-adrenergic receptors (β2-ARs) through
activation of the α subunit of the associated G protein (Gαs) by exchanging its bound guanosine
diphosphate (GDP) to guanosine triphosphate (GTP) (181, 182). The activated Gαs, together with
GTP, then dissociates from the β and γ subunit to further stimulate adenylyl cyclase (AC) (183,
184). AC catalyzes the conversion of adenosine triphosphate (ATP) to cAMP which then activates
PKA (172, 185). PKA, in turn, phosphorylates ICAM-4. The cAMP-PKA pathway is described in
appendix 2.A (2.A.1 and Figure 2.A.1).

Our group first demonstrated that scaffold proteins termed A-kinase anchoring proteins (AKAPs)
are critical for mediating adherence of RBC BCAM/Lu receptors to laminin (172). The AKAP family
includes ~50 structurally diverse, but functionally similar scaffolding proteins which contain (i) a
common PKA-anchoring domain that binds to the regulatory subunit of PKA (186-188) and (ii) a
unique subcellular targeting domain guiding the PKA-AKAP complex (181, 189, 190). AKAPs
anchor PKA to specific subcellular sites, thereby guiding PKA activity towards specific locations
in the cell, such as the plasma membrane (191) where PKA can alter the phosphorylation state
of neighboring RBC receptors (186). It is postulated that it is by this mechanism that AKAPs
mediate cAMP-PKA dependent activation of RBC adhesion receptors (172).

In this study, we extend our work to investigate the effects of the cAMP-PKA pathway
manipulation on (i) the binding between ICAM-4 and αvβ3 and (ii) the expression of active ICAM-
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4 receptors on the membrane of both WT-RBCs and SS-RBCs. We also investigate whether
AKAPs play a role in ICAM-4 activation. We implement single molecule force spectroscopy
(SMFS) by using an atomic force microscope (AFM) which allows for the detection of single
functional receptors on cells and at the same time measurement of the unbinding force between
a receptor and the corresponding ligand (172, 192-198). It also allows detection of variations in
the collective frequency (CF) of active ICAM-4 receptors on the RBC membrane. We use several
biochemical reagents that manipulate the cAMP-PKA pathway and the AKAP-PKA complex to
regulate ICAM-4 activation. In addition, we used confocal microscopy to corroborate our AFM
results.

Our experiments confirmed, at the single molecule level, that the activation of the ICAM-4
receptors depends upon the cAMP-PKA pathway. We found that the surface expression of active
ICAM-4 receptors in WT-RBCs and in SS-RBCs are not significantly different using both SMFS
and confocal microscopy. We also showed that epinephrine increased the expression of active
ICAM-4 receptors in RBC samples from both healthy donors and SCD patients. Importantly, we
demonstrated that this activation is mediated by AKAPs. In addition, we found that while the CF
of active ICAM-4 receptors was modulated via the cAMP-PKA pathway, the mean value of the
unbinding force between active ICAM-4 and αvβ3 did not change even at higher surface
expressions of active ICAM-4. This means that activation of ICAM-4 did not alter the unbinding
force and that nanoclusters of ICAM-4 receptors were not formed in detectable numbers. This
result along with the finding that epinephrine activates ICAM-4 in both WT- and SS-RBCs
contrasts results based on flow chamber assays where epinephrine did not significantly increase
ICAM-4-dependent adhesion on WT-RBC. The findings of this work might be of clinical
importance in the context of drug development for prevention and treatment of VOE in SCD by
hindering enhanced adhesion events between RBCs and the endothelium by introducing
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biomedical reagents that not only act along the cAMP-PKA pathway but also on the AKAP-PKA
complex.

2.2. Materials and methods
Human subjects and blood preparation
Our clinical protocol was approved by the Institutional Review Boards of UCONN Health and
UCONN-Storrs. Inclusion/exclusion criteria for healthy volunteers: Healthy volunteers were
eligible provided they were at least 7 years old and had a normal hemoglobin electrophoresis.
Healthy volunteers were excluded from the study if they were pregnant, breast-feeding, or within
3 months post-partum, used anti-lipid therapy within the previous week, were taking an
investigational drug, or received a blood transfusion within the previous 3 months.
Inclusion/exclusion criteria for homozygous SCD (SS) patients: SCD patients were included in the
study if they had documented homozygous SS disease, were at least 7 years old, and were in
steady state. Steady state was defined as not having received parenteral opioid administration in
the last 4 weeks, had pain no greater than the usual daily level for 4 weeks, and no increase in
usual non-parenteral opioid medication utilization in the past 4 weeks. SCD patients were
excluded from the study if they were pregnant, breast-feeding, or within 3 months post-partum,
used anti-lipid therapy within the previous week, were taking an investigational drug, treated with
hydroxyurea (HU), or received a blood transfusion within the previous 3 months. HU treatment
was an exclusion criterion because HU has been shown to affect RBC adhesion to laminin by
inhibiting phosphorylation of BCAM/Lu (172, 199) and we reasoned that HU might act in a similar
way to inhibit activation of ICAM-4. None of the SCD subjects had chronic organ damage.
Demographic and clinical characteristics of subjects are found in Table 2.1.
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Table 2.1. Demographic and clinical characteristics of the blood donors
SCD Patient

Healthy Volunteer
n=4

n=3

Age, mean, SD

26 (5)

Age, mean, SD

40 (3)

Gender, n, %
Male

4 (100)

Gender, n, %
Female

3 (100)

Race, n, %
African American

4 (100)

Race, n, %
African American
White

2 (67)
1 (33)

Genotype, n, %
HbAA

3 (100)

Genotype, n, %
HbSS

4 (100)

Hemoglobin, g/dL, mean, SD

9 (0)

Hemoglobin, g/dL, mean, SD

13 (1)

Leukocyte count, K/μL, mean, SD

14 (2)

Leukocyte count, K/μL, mean, SD

6 (2)

Platelet, K/μL, mean, SD

502 (181)

Platelet, K/μL, mean, SD

284 (64)

Neutrophil, %, mean, SD

53 (15)

Neutrophil, %, mean, SD

57 (10)

Reticulocytes, %, mean, SD

13 (5)

LDH, U/L, mean, SD

444 (66)

Blood samples were obtained from fresh-drawn, heparin-anticoagulated venous blood of eligible
volunteers after obtaining informed consent. Whole blood was centrifuged at 145 ×g for 5 min at
4℃ to separate the RBCs. The plasma and buffy coat were extracted and discarded. Then, the
remaining RBCs were washed three times with Alsever’s solution and stored at 4℃ for up to seven
days. We note that the experiments were performed in normal not-hypoxic conditions. The reason
is that hypoxia (65) and the consequent change in the viscoelastic properties of SS-RBCs (200)
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may play a role in the variation RBC adhesion adding another parameter to the main focus of this
paper which is the cAMP-PKA pathway. We also note that in SS patients the reticulocyte count
average was 13 ± 5 % (see Table 2.1), increased compared to healthy donors where the
reticulocyte count is typically close to 0.5-2% (201). In our experiments, we chose to test only
RBCs having the characteristic biconcave shape in order to exclude reticulocytes, which typically
have irregular shapes in our samples (see 2.A.2 and Figure 2.A.2).

Ligand and reagents

Human integrin αvβ3 protein (100 μg/mL, diluted with PBS) was obtained from Millipore (Billerica,
MA). Alsever’s solution, epinephrine (16.39 nM, reconstituted in Alsever’s solution), forskolin (FSK;
0.49 μM, reconstituted in DMSO), and bovine serum albumin (BSA; 100 μg/mL, reconstituted in
PBS) were purchased from Sigma-Aldrich (St. Louis, MO). St-Ht31 inhibitor peptide and St-Ht31P
control peptide (both 81.97 nM, reconstituted in Alsever's solution) were purchased from Promega
(Madison, WI). RBCs were treated with the reagents above at 37o for 30 min unless otherwise
indicated.

AFM cantilever probe functionalization

Soft silicon nitride cantilevers with silicon nitride tips were purchased from Bruker Nano Inc.
(Camarillo, CA). The tip height is between 2.5 and 8 μm and the nominal tip radius is 20 nm. The
nominal spring constant of the applied cantilever is 30 pN/nm. The actual spring constant under
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the experimental condition (in Alsever’s solution at 37℃) was calculated by a thermal noise based
method (202, 203).

Glutaraldehyde functionalization: Silicon nitride probes (Bruker AFM Probes, Camarillo, CA) were
first amino-functionalized with 2% v/v 3-aminopropyltriethoxysilane (APTES) in acetone (Sigma
Aldrich, St. Louis, MO) for 10 min, then rinsed with deionized (DI) water. Probes were soaked in
0.5% v/v glutaraldehyde (solution in DI water) for 30 min then rinsed again with DI water and
incubated in 100 μg/mL αvβ3 solution. After 30 min, the probes were rinsed with DI water and
immersed in 100 μg/mL BSA for 1 min to block the remaining aldehyde groups. Probes were
stored in PBS at 4℃ and used within three days.

Acetal-PEG-NHS-αvβ3 functionalization: Silicon nitride probes were functionalized with αvβ3 via
acetal-PEG-NHS (Institute of Biophysics, Johannes Kepler University, Linz, Austria) following
manufacturer instructions (http://www.jku.at/biophysics/content).

AFM setup and data recording

Experiments were performed using the MFP-3D-BIO AFM (Asylum Research, Santa Barbara,
CA), which was mounted on an inverted microscope (Zeiss Axiovert A1). Using the microscope,
we were able to position the AFM cantilever on a chosen RBC (Figure 2.1 A) that was less than
10 μm in diameter and possessed an explicit circular biconcave shape indicative of RBC maturity
and functionality. RBCs were pretreated with specific biomedical reagents and incubated at 37℃
(30 min for epinephrine, FSK; 2h for St-Ht31, St-Ht31P). For each reagent, five RBCs were tested
from each subject. RBCs were seeded in a glass bottom petri dish (Ted Pella, Inc., Redding, CA)
which was pre-treated with 1 mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 15
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min at room temperature. At these conditions, RBC adhered slightly to the substrate while they
maintained their biconcave shape. During the cantilever retraction, RBCs were not pulled off the
substrate as we could clearly determine via the inverted microscope.

Figure 2.1. Single molecule force spectroscopy. (A) Optical microscopy image showing the
shadow of an AFM cantilever and a representative human RBC. The scale bar corresponds to
10 μm. (B) Force curve plot exhibiting an unbinding event. The red curve represents the
approach of the cantilever to the RBC surface membrane while the blue curve represents the
retraction of the cantilever from the RBC. The sharp change in the magnitude of the retraction
force signifies the unbinding force.

Adhesive interactions were quantified by recording force-distance curves at 32×32 points,
distributed in a 1μm2 area of the RBC membrane, between an αvβ3-functionalized cantilever and
ICAM-4 receptors expressed on the RBC membrane. Each curve recorded a complete approach
and retraction cycle. We have shown that measurement at 1024 points uniformly distributed in a
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1μm2 area gives a representative result for the specific tested RBC. We note that because AFM
experiments (and the following data processing) are time-consuming and often detrimental to
tested cells, we have standardized the optimum scanning area for SMFS experiments on RBCs
to be 1 μm2 in (167). The AFM data were processed using our in-house developed code named
FRAME (Force Review Automation Environment) (204). An unbinding force was determined as
the magnitude of the abrupt drop to zero on the retraction force-displacement curve with a rupture
event (Figure 2.1B). The approach and retraction speed was 800 nm/s which gave a nominal
loading rate of 24,000 pN/s. At this speed, the unbinding measurements were not significantly
affected by hydrodynamic forces (205). A specific trigger point/threshold was set to control the
indentation depth and to ensure that the same nominal maximum force was applied to each RBC.
The corresponding probe travel distance was ~200 nm which meant the probe was in contact with
the RBC membrane for ~1/4 s before retraction. We only considered the interactions for which
the effective spring constants (keff) were less than 10 pN/nm which, in combination with the
retraction speed, ensures that the influence of keff is not significant for SMFS experiments (206).
The effective spring constants were obtained from the slopes of the curves adjacent to the
unbinding force drops (207, 208). The unbinding forces were plotted as a force map displaying
the spatial distribution of the active ICAM-4 receptors on the RBC surface (Figure 2.2A). The color
of each spot represented the value of the unbinding force obtained from the corresponding
retraction path. CF% is defined as the percentage of all unbinding events divided by the total
number of measurements, which is 32x32=1024 for each cell multiplied by the number of tested
cells for each subject’s blood sample. CF represents the population of active ICAM-4 receptors
capable of binding to αvβ3. This approach allowed observation of changes in the force maps due
to modulation of the CF of activated ICAM-4 receptors in the presence of biochemical reagents
that interfere with the cAMP-PKA pathway and the AKAP-PKA complex.
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Figure 2.2. Distribution of active ICAM-4 receptors and unbinding force between αvβ3
and ICAM-4. (A) Representative force maps from a 1μmx1μm area of an individual RBC (i) at
baseline, (ii) treated with 16.39 nM epinephrine, and (iii) treated with 16.39 nM epinephrine and
1.29 μg/mL bath αvβ3 to block activated ICAM-4. Scale bars, 250 nm. Color scale as shown
indicates the magnitude of the unbinding force. (B) Frequency distributions of unbinding forces
between ICAM-4 and αvβ3 in WT-RBCs. (C) Box-and-whisker plot of the CF of active ICAM-4
receptors on WT-RBCs. Data are shown as median with min and max whiskers and the mean
denoted as a color dot. The ‘n’ on the x-axis indicates the total number of mature WT-RBCs
analyzed in each group, obtained from the following numbers of human subjects: Baseline: 3
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subjects; + Epinephrine: 3 subjects. + Epinephrine + bath αvβ3: 1 subject. Significance relative
to baseline or between conditions is denoted as * for p<0.0001. (D) Frequency distributions of
unbinding forces between ICAM-4 and αvβ3 in SS-RBCs. (E) Box-and-whisker plot of the CF
of active ICAM-4 receptors on SS-RBCs. Data are shown as median with min and max whiskers
and the mean denoted as a color dot. The ‘n’ on the x-axis indicates the total number of mature
SS-RBCs analyzed in each group, obtained from the following numbers of human subjects:
Baseline: 4 subjects; + Epinephrine: 4 subjects. + Epinephrine + bath αvβ3: 1 subject.
Significance relative to baseline or between two conditions is denoted as * for p<0.0001.

Binding specificity of αvβ3 ligands to ICAM-4 receptors
It is known that in mature RBCs, ICAM-4 is the major receptor for the endothelial integrin αvβ3
(171, 179). To show that our measurement technique is specific to αvβ3, we first performed
experiments on RBCs from healthy volunteers to obtain the baseline CF of active ICAM-4
receptors and unbinding forces between the αvβ3 ligand and ICAM-4 receptor. Figure 2.2A (i)
shows a representative force map recorded during the surface scan. There are 32×32 pixels in
each force map. The color of the pixels indicates the force values ranging between 0 and 100 pN
according to the color scale shown in Figure 2.2A. We show that treatment of RBCs from healthy
subjects with epinephrine, a catecholamine which binds to the β2-adrenergic receptor and
activates the cAMP-PKA dependent pathway, significantly increases the CF of active ICAM-4
receptors (Figure 2.2C) compared to baseline. When we first treated the sample with epinephrine
and then with bath αvβ3, we saw a dramatic decrease in the CF of detected unbinding events
compared to the CF measured when the sample was incubated only with epinephrine (Figure
2.2A(iii), C), suggesting that αvβ3 in the bath blocked most of the active ICAM-4 receptors on the
RBC membrane. In addition, we performed experiments with a cantilever treated with APTES,
glutaraldehyde, and BSA but not with αvβ3 (non-functionalized cantilever). The recorded CF was
negligible (0.62%) meaning that αvβ3 is indeed the functional protein on the cantilever tip (see
2.A.3 and Figure 2.A.3). In addition, this measurement defined the background noise of the SMFS
method for the specific assay described here.
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Immunocytochemistry
70µL of normal or sickle blood was added to assigned wells containing poly-D-lysine coated
coverslips and incubated at 37°C for 15 minutes. Following incubation, cells were washed with
Dulbecco’s PBS (dPBS, ThermoFisher Scientific, Waltham, MA) and incubated with 16.39nM
epinephrine (Sigma-Aldrich, St. Louis, MO) or 1μL DI water carrier for 30 minutes at 37°C.
1.29µg/mL human integrin αvβ3 protein (Millipore, Billerica, MA) was added to all the wells for 30
minutes

at

37°C

followed

by

washing

with

dPBS.

Cells

were

then

fixed

with

2%Paraformaldehyde/4% Sucrose/PBS for 5 minutes at room temperature. After washing with
dPBS and blocking with pre-block buffer (20mM phosphate buffer, pH 7.4, 5% normal goat serum,
450mM NaCl) for 1 hour at 4°C, cells were incubated with mouse anti-integrin αvβ3 antibody
(1:500, Abcam, Cambridge, MA, Cat# ab78289) primary antibody in pre-block buffer overnight at
4°C.

The next day, cells were incubated with pre-block buffer for 1 hour at 4°C and then incubated with
goat anti-mouse Alexa Fluor 488 (1:500, Abcam, Cambridge, MA, Cat# ab150113) secondary
antibody in the pre-block buffer for 2 hours in the dark. Cells were then washed with dPBS and
coverslips were mounted on glass slides using prolong Diamond (ThermoFisher Scientific,
Waltham, MA) mounting media.

Image acquisition
All images were taken on a laser-scanning Leica SP8 (Leica Microsystems, Wetzlar,
Germany) confocal microscope. Z-stacks were taken with a step size of 0.25μm. Imaging
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conditions for all the paraformaldehyde-fixed cells were as follows: 63X oil immersion lens was
used to view the cells; the pinhole size was set at 1 airy unit; the raw images were exported as .tiff
files and viewed on NIH Image J software. For all the acquired images, only brightness and
contrast for the entire frame was adjusted on Image J and no singular section of the frame was
modified in any way.

Image quantitation
Z-stacks from the same cell were projected using the Z-project function of Image J software. To
quantify the fluorescence intensity of the green (active ICAM-4) channel, a region of interest (ROI)
was chosen and the measurement analysis was set to yield the area, min and max pixel strength,
integrated and raw density and mean grayscale value. The raw values were exported to Excel.
The corrected total fluorescence (CTF) was calculated for the chosen ROIs for cells in different
conditions. CTF is the resultant output of subtracting the mean background intensity over the
chosen ROI from the integrated density for each ROI.

Statistical analysis
The unbinding forces between αvβ3 ligands and ICAM-4 receptors are reported using frequency
(%) distribution which states the percentage of events whose unbinding forces are within each
bin's width. We then compare the median values of the forces measured in experiments without
and with treatment with different reagents. The zero force points are not shown because they
would obscure the plots since their population is much larger than the population of unbinding
events. CF% is related to the population of active ICAM-4 receptors and it is defined as the
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percentage of all unbinding events divided by the total number of measurements, which is
32x32=1024 for each cell multiplied by the number of tested cells for each blood sample. The CF
and CTF results are reported as mean ± standard error (SE) and illustrated by box-and-whisker
plots (GraphPad Prism, GraphPad Software, Inc.). They are compared using one-way analysis of
variance (ANOVA) and the Tukey-Kramer post hoc test. The results are considered significant if
p<0.05.

2.3. Results and discussion

Epinephrine increases the surface density of active ICAM-4 receptors on normal and SSRBCs but not the unbinding force between ICAM-4 and αvβ3.
Epinephrine is a hormone whose action is mediated by the beta-adrenergic receptor, a seventransmembrane domain receptor that can activate guanine nucleotide regulatory binding proteins
(G protein-coupled receptors) (209). It has been previously shown that activation of the cAMPPKA dependent pathway by epinephrine increases adhesion of sickle but not normal RBCs to
endothelium via ICAM4-αvβ3 interaction (171). The experimental technique employed in these
studies was based on the flow chamber assay which measures the overall RBC adhesion and
not directly the population of functional adhesion receptors or the strength of interactions between
ligand-receptor pairs.

Here, we used the SMFS assay that, as established in our previous work (172, 173), can detect
variations of the surface density of active adhesion receptors on the RBC membrane (i.e., CF %)
and record unbinding forces between receptors and ligands. We scanned a 1μm2 area of
individual RBC membranes with an AFM cantilever functionalized with αvβ3 to directly detect the
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population of active ICAM-4 receptors under different experimental conditions. We first tested
RBCs from healthy volunteers (WT-RBCs) at baseline and after in vitro treatment with epinephrine.
Force maps shown in Figure 2.2A (i, ii) clearly illustrate that epinephrine increases the CF of
active ICAM-4 receptors. However, epinephrine had no effect on the median unbinding force
(Figure 2.2B, Table 2.2) suggesting epinephrine only affects the activation of ICAM-4 receptors
and not the strength of their interaction with αvβ3 ligand.

Table 2.2. Unbinding forces between ICAM-4 and αvβ3 and collective frequencies of active ICAM4 receptors for WT-RBCs and SS-RBCs
Unbinding force (median, pN)
WT
SS

Collective frequency (mean ± SE, %)
WT
SS

Test condition
Baseline
24.59
23.59
7.10±1.26
10.08±0.85
+epi
24.27
24.53
23.63±2.23
21.41±2.27
+epi+bath αvβ3
*
*
1.43±0.37
1.78±0.31
+FSK
24.08
24.70
25.91±3.71
26.55±2.68
+St-Ht31+FSK
27.45
26.09
7.80±2.16
9.22±1.52
+St-Ht31P+ FSK
*
36.56±8.73
+St-Ht31P
25.09
21.94
7.56±1.81
10.12±2.32
* There was not enough non-zero unbinding force data to generate an accurate median value.

To establish a measure of the overall quantity of active ICAM-4 receptors, we calculated the CF.
The results are reported in box-and-whisker plots in Figure 2.2C. We found that the mean value
of the CF increased significantly from 7.1% in baseline experiments to 23.63% when the blood
sample was treated with epinephrine (p<0.0001). This suggests that epinephrine triggers
activation of ICAM-4 receptors on WT-RBCs probably via the cAMP-PKA pathway.

Next, we tested RBCs obtained from volunteers with SCD (SS-RBCs). We measured the CF of
ICAM-4 receptors with and without treatment with epinephrine. Similar to WT-RBCs, we found
that the median unbinding force between ICAM-4 and αvβ3 did not significantly change (Table
2.2, Figure 2.2D). The CF of ICAM-4 adhesion was measured to be 10.08±0.85% for SS-RBCs
without epinephrine treatment, higher than in the case of WT-RBCs, although not significant
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(p=0.06). Treatment of SS-RBCs with epinephrine increased the CF significantly to 21.41±2.27%
(Figure 2.2E, p<0.0001, Table 2.2).

Our results are in agreement with previous experimental results showing that epinephrine
increases adhesion of SS-RBCs to endothelium (171). Moreover, our findings give additional
information that this increase is due to the increased number of active surface ICAM-4 and not
due to increased unbinding force between ICAM-4 and αvβ3. We note, however, that Zennadi et
al. did not detect a significant effect of epinephrine on WT-RBC adhesion to human umbilical vein
endothelial cells (HUVECs) (171). One reason for this discrepancy might be that they incubated
blood samples with 20 nM epinephrine for only 1 min at 37 ˚C while we incubated them with 16.39
nM epinephrine for 30 min at 37 ˚C. Another possible explanation is that their method is not as
sensitive to detect changes when the overall adhesion is low. They used intermittent flow
conditions in a flow chamber and they reported the ratio of the number of RBCs adhered to
HUVECs after exposure to flow conditions over the number of initially adherent RBCs before
exposure to flow while we directly measured the surface density of ICAM-4 at the single molecule
level. Cell-cell and cell-matrix adhesion may be influenced not only by the number of adhesion
pairs between molecules expressed on the cells but also on mechanical properties of cells (200,
210). Our results, based on SMFS, give direct evidence that the unbinding force between ICAM4 and αvβ3 did not change when the cells were incubated with epinephrine meaning that ICAM4 activation did not alter the interaction between ICAM-4 and αvβ3 and did not cause the formation
of nanoclusters. We finally note that these conclusions cannot be drawn using methods that
directly measure RBC adhesion such as microfluidics or single-cell force spectroscopy (SCFS).

To validate the specificity of our measurements, we added αvβ3 to the bath solution. We expected
the bath αvβ3 to bind to activated ICAM-4 receptors on the RBC membrane thereby inhibiting
cantilever-bound αvβ3 from binding to ICAM-4 on the RBC surface. Indeed, binding significantly
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decreased in both WT-RBCs (CF 23.63±2.23 vs. 1.43±0.37%, p<0.0001) and SS-RBCs (CF
21.41±2.27 vs. 1.78±0.31%, p<0.0001) (Figure 2.2, Table 2.2). These results confirmed that
indeed it is αvβ3 that binds to the receptors on the RBC membrane and not other substances
attached to the cantilever such as glutaraldehyde. Since our AFM cantilever functionalization
technique involves the use of glutaraldehyde (211, 212) to attach the αvβ3 molecules to the
cantilever, we wanted to test if glutaraldehyde, with its inability to control the number of αvβ3
molecules attached to the cantilever, would skew the results. To this end, we functionalized AFM
cantilevers with αvβ3 via an acetal-PEG-NHS linker, instead of glutaraldehyde, which guarantees
that the probability the AFM cantilever is functionalized with only one molecule is greater than 50%
(213) (Figure 2.3A, B). As demonstrated in Figure 2.3, we probed SS-RBCs at baseline and we
found that both functionalization methods gave almost identical results with respect to unbinding
force (23.08 pN for the glutaraldehyde functionalization vs. 25.85 pN for the acetal-PEG-NHS
functionalization, p = 0.8451), and CF (7.37±1.45% for the glutaraldehyde functionalization vs.
8.44±1.75% for the acetal-PEG-NHS functionalization, p = 0.6943, data not shown). This result
means that ICAM-4 receptors expressed on the RBC membrane do not form nanoclusters since
the median values of the measured unbinding forces are similar in both techniques. If the
receptors had formed nanoclusters then higher unbinding forces would have been recorded
forming a second peak in the unbinding force histogram as it is the case in Abiraman et al. (198).
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Figure 2.3. Comparison of ICAM4-αvβ3 unbinding forces measured using
Glutaraldehyde-based vs. PEG-based AFM cantilever functionalization. (A) Schematic of
Glutaraldehyde-αvβ3 functionalized tip probing ICAM-4 molecules on the RBC membrane. (B)
Schematic of acetal-PEG-NHS- αvβ3 functionalized tip probing ICAM4 molecules on the RBC
membrane. (C) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 on SSRBCs for Glutaraldehyde-based (black) and PEG-base (red) AFM cantilever functionalization.
The same samples were used in both methods (2 subjects, n=10).

Confocal microscopy experiments confirm SMFS-based results
We performed confocal microscopy experiments to image active ICAM-4 receptors on RBCs to
further confirm our SMFS-based findings. Both WT-RBCs and SS-RBCs were incubated with
αvβ3 (1.29µg/ml for 30 min) in order to tag active ICAM-4. The RBCs were then washed
thoroughly to remove any unbound αvβ3, fixed and stained with an anti-αvβ3 antibody which
labeled the αvβ3 bound to the active ICAM-4. Alexa Fluor 488 was used to visualize active ICAM4. We found that, similar to our AFM experiments, there was no significant difference in active
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ICAM-4 expression between WT-RBCs and SS-RBCs (Figure 2.4A-C, WT: corrected total
fluorescence (CTF) = 9.72±0.63, n=16; SS: CTF= 11.79±0.47, n=16; p=0.794).

Figure 2.4. Confocal microscopy results showing the active ICAM-4 receptors on RBCs.
WT and SS-RBCs were incubated with 16.39nM epinephrine or 1μl DI water carrier, then
incubated with αvβ3 to label active ICAM-4, fixed and stained with an anti-αvβ3 antibody which
labeled the αvβ3 bound to active ICAM-4. Representative confocal microscopy images of (A)
WT-RBC (n=16) and WT-RBC + Epinephrine (n=10) (B) SS-RBC (n=16) and SS-RBC +
Epinephrine (n=16). (C) Box-whisker plots of the corrected total fluorescence of active ICAM-4
receptors on WT-RBCs and SS-RBCs with or without epinephrine treatment. The data are
represented as mean ± SE *, p=0.0339, **, p=0.0042, n.s., no significant difference (one-way
ANOVA) (1subject).
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However, when WT-RBCs and SS-RBCs were incubated with epinephrine (16.39nM for 30 min
at 37ºC) prior to being fixed and stained with anti-αvβ3 antibody, we found a significant increase
in active ICAM-4 expression compared to baseline in both cases (Figure 2.4A-C, WT: CTF=
16.29±1.91, n=10, p=0.033; SS: CTF= 17.01±0.92, n=16, p<0.0001). In addition to the confocal
experiments, we performed AFM experiments on the same samples to compare the CF of
unbinding events between WT- and SS-RBCs at baseline and when the cells were incubated with
epinephrine. We found that there was no significant difference in the CF of unbinding events
between WT- and SS-RBCs (p > 0.5) and the addition of epinephrine caused a significant
increase in the CF of unbinding events compared to baseline in both WT- (p=0.035) and SSRBCs (p=0.01) (Figure 2.A.4). These results are in agreement with the results of the confocal
microscopy experiments performed with the same samples and with the overall AFM results
discussed in the first section.

Activation of ICAM-4 on WT-RBCs and SS-RBCs is regulated by the cAMP-PKA dependent
pathway
It is known that epinephrine binding of the β-AR activates the cAMP-PKA dependent pathway.
Furthermore, Zennadi et al. demonstrated that SS-RBC adhesion is regulated by the same
pathway (171). Using SMFS, we tested at the single-molecule level if the increased CF of active
ICAM-4 receptors on WT-RBCs and SS-RBCs is controlled by the cAMP-PKA pathway. We
introduced pharmacologic regulation by using biomedical reagents that act along the cAMP-PKA
pathway. We first pre-treated WT-RBCs with FSK (0.49 μM), an AC activator which strongly
activates PKA. Compared to baseline, FSK-treated WT-RBCs exhibited no difference in unbinding
force (24.59 vs. 24.08pN, p=0.26, Figure 2.5A, Table 2.2) but a significantly higher CF (7.10±1.26
vs. 25.91±3.71%, p<0.0001, Figure 2.5B, Table 2.2). In agreement with the results of WT-RBCs,
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we detected similar unbinding force (23.59 vs. 24.70 pN, p=0.32, Figure 2.5C, Table 2.2) and
significantly increased CF in SS-RBCs pre-incubated with FSK (0.49 μM) compared to baseline
(26.55±2.68 vs. 10.08±0.85%, p<0.0001) (Figure 2.5D, Table 2.2). This indicates that the CF of
active ICAM-4 receptors on WT- and SS-RBCs is regulated by the cAMP-PKA dependent
pathway and that the strength of adhesive interactions is not affected. We also conclude that
because the strength of unbinding forces did not significantly change, clustering of ICAM-4
receptors was unlikely.

Figure 2.5. Unbinding forces between ICAM4 and αvβ3 and the number of active ICAM4 receptors with the absence and presence of FSK. (A) Frequency distributions of unbinding
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forces between ICAM4 and αvβ3 in WT-RBCs in the presence of PKA activator FSK (0.49μM).
(B) Box-whisker plots showing the CF of active ICAM-4 receptors on WT-RBCs in the presence
of FSK. Significance relative to baseline is denoted as * such that p<0.0001. The ‘n’ on the xaxis indicates the total number of WT-RBCs analyzed in each group, obtained from: Baseline:
3 subjects; FSK: 3 subjects. (C) Frequency distributions of unbinding forces between ICAM-4
and αvβ3 in SS-RBCs in the presence of FSK (0.49μM). (D) Box-whisker plots showing the CF
of active ICAM-4 receptors on SS-RBCs in the presence of FSK. Significance relative to
baseline is denoted as * such that p<0.0001. The ‘n’ on the x-axis indicates the total number of
SS-RBCs analyzed in each group, obtained from: Baseline: 4 subjects; FSK: 4 subjects.

ICAM-4 receptor activation is dependent on AKAPs
It is known that the action of PKA is localized to specific sub-membrane domains through PKA
binding to AKAPs (181, 189, 190). Based on this, we investigated if AKAPs, located in the RBC
membrane, play a role in the PKA-dependent activation of ICAM-4 receptors. To examine this,
we used St-Ht31, a membrane-permeable peptide (214) comprising a PKA-anchoring domain
that inhibits the binding of PKA to AKAPs (215). As we discussed above, FSK activates AC, which
in turn activates PKA and causes a significant increase in the CF of active ICAM-4 receptors on
WT- and SS-RBCs. To demonstrate that ICAM-4 is activated via AKAPs, we incubated RBCs with
St-Ht31 (2 hours) and FSK (30 min) sequentially. In this case, the CF of active ICAM-4 on WTRBCs was detected to be 7.80±2.16 % in contrast to 25.91±3.71% obtained when only FSK was
applied (Figure 2.6A, p<0.0001, Table 2.2). Similarly, on SS-RBCs, CF was found to be
9.22±1.52 % compared to 26.55±2.68 % when only FSK was applied (Figure 2.6B, p<0.0001,
Table 2.2). To confirm that the decrease was not due to a direct interaction between St-Ht31 and
FSK, we pretreated SS-RBCs with St-Ht31P control peptide which differs from St-Ht31 by
isoleucine-to-proline substitutions and thus can no longer bind to PKA (215). We found that in this
case, the CF increased significantly (36.56±8.73%, p<0.0001, Table 2.2) demonstrating that
indeed St-Ht31 inhibits activation of ICAM-4. When WT- and SS-RBCs were incubated solely with
the control peptide St-Ht31P, the CF was similar to untreated samples (7.56±1.81% for WT-RBCs
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and 10.12±2.32% for SS-RBCs, Table 2.2). These results suggest that inhibition of AKAP-PKA
complex suppresses the activation of ICAM-4 receptors in both WT- and SS-RBCs.

Figure 2.6. Modulation of active ICAM-4 via AKAPs on the RBC membrane. Box-whisker
plots of the CF of active ICAM-4 receptors on (A) WT-RBCs and (B) SS-RBCs for the reagents
indicated on the x-axis. The ‘n’ on the x-axis indicates the total number of mature RBCs
analyzed in each group, obtained from the following numbers of human subjects: (i) for WTRBCs, Baseline: 3 subjects; St-Ht31P: 3 subjects; St-Ht31 (81.97 nM) + FSK (0.49μM): 3
subjects. (ii) For SS-RBCs, Baseline: 4 subjects; St-Ht31P: 4 subjects; St-Ht31 (81.97 nM) +
FSK (0.49μM): 4 subjects; St-Ht31P (81.97 nM) + FSK (0.49μM): 1 subject. Significance relative
to baseline or between conditions is denoted as * such that p<0.0001.

2.4. Conclusions

In this study, we investigated at the single-molecule level the modulation of the surface density of
active ICAM-4 receptors on WT- and SS-RBCs using SMFS and confocal microscopy. While it
was known that epinephrine acts via the cAMP-PKA pathway to modulate the overall adhesion of
SS-RBCs to ECs, the mechanisms by which epinephrine acts at the single molecule level was
not known. Here, we demonstrated that epinephrine increases the surface expression of active
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ICAM-4 receptors in both WT- and SS-RBCs. Furthermore, we confirmed that the activation of
ICAM-4 receptors is regulated via the cAMP-PKA pathway and importantly we determined for the
first time that this activation is mediated by AKAPs. In addition, we showed that while the CF of
active ICAM-4 receptors was modulated via the cAMP-PKA pathway the median value of the
unbinding force between active ICAM-4 and αvβ3 did not change even at higher surface
expressions of active ICAM-4. This means that activation of ICAM-4 did not alter the unbinding
force between ICAM-4 and αvβ3 and that nanoclusters of ICAM-4 were not formed in detectable
numbers. This result along with the finding that epinephrine activates ICAM-4 in both WT- and
SS-RBCs contrasts results based on flow chamber assays showing that epinephrine did not
significantly increase ICAM-4-dependent adhesion on WT-RBC. Overall, our data might be of
clinical importance in the context of drug development for prevention and treatment of VOE in
SCD since they suggest that adhesion of RBCs to endothelial cells can be modulated, especially
during stress conditions, by the introduction of biomedical reagents acting along not only the
cAMP-PKA pathway but also on the AKAP-PKA complex.

2.5. Appendix 2.A

2.A.1. cAMP-PKA dependent pathway and AKAPs
One important mechanism of ICAM-4 activation is via the cyclic adenosine monophosphateprotein kinase A (cAMP-PKA) dependent signaling pathway (Figure 2.A.1) which can be mediated
by A-kinase anchoring proteins (AKAPs). Activation of RBC β2-adrenergic receptors (β2-ARs),
induced by epinephrine, activates the α subunit of the associated G protein (Gαs) by exchanging
its bound guanosine diphosphate (GDP) to guanosine triphosphate (GTP). The activated Gαs,
together with GTP, then dissociates from the β and γ subunit to further stimulate adenylyl cyclase
40

(AC). AC (which can be directly activated, e.g. by forskolin) catalyzes the conversion of adenosine
triphosphate (ATP) to cAMP which then activates PKA. A kinase anchoring protein (AKAPs)
anchors PKA to specific sites on the plasma membrane where PKA can alter the phosphorylation
state of neighboring ICAM-4 receptors thereby causing their activation. (See (183, 184, 186)).

Figure 2.A.1. RBC cAMP-PKA dependent pathway.

2.A.2. Reticulocytes
Thiazole orange has been proved to be an ideal fluorescent dye for reticulocyte analysis due to
its good quantum yield, enhancement of fluorescence with RNA, membrane permeability, simple
staining procedure, and ability to count as many reticulocytes as new methylene blue and was
therefore used to identify reticulocytes in the petri dish containing blood sample (216). The
following protocol was employed: (1) Stock solution of 1 mg/mL Thiazole orange (purchased from
Sigma-Aldrich, St. Louis, MO) in methanol was made. (2) The stock solution was diluted to 3×107

M in phosphate-buffered saline. (3) RBCs were seeded on a glass bottom petri dish, as we do
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for adhesion measurements, then 1mL 3×10-7 M Thiazole orange solution was added and
incubated at room temperature for 1h. (4) Cells were then observed under fluorescence
microscopy to identify reticulocytes (Figure 2.A.2 A and B). As for the unstained control (Figure
2.A.2 C and D), we followed the same protocol as described above but added PBS instead of
Thiazole orange solution in step (3).

The reticulocyte count of the tested sample was 11.3%. Figure 2.A.2 A and B are representative
bright-field and fluorescent microscopy images respectively of Thiazole orange stained RBCs.
They show a representative area which contained both reticulocytes (in colored circles) which
were excluded from our measurement and biconcave RBCs which were tested (in green triangles)
to detect unbinding events. Figure 2.A.2 C and D are representative bright-field and fluorescent
microscopy images respectively of unstained RBCs. As expected we did not observe any
fluorescence.
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Figure 2.A.2. Differentiating reticulocytes using Thiazole orange. (A) Optical microscopy
image of RBCs in Thiazole orange solution (B) Fluorescent microscopy image of RBCs in Thiazole
orange solution. (C) Optical microscopy image of RBCs in PBS. (D) Fluorescent microscopy image
of RBCs in PBS. The scale bar corresponds to 20μm.

2.A.3. Results from the control experiments related to BSA coating of the probe
Here, we compare the histograms of unbinding forces and CF box-whisker plots of unbinding
events between SS-RBCs and a probe coated with αvβ3 and then with BSA versus a cantilever
coated only with BSA. We found a negligible number of unbinding events for non-αvβ3 coated
probes.
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Figure 2.A.3. Comparison of adhesion between non-αvβ3 and αvβ3 coated probes. (A)
Frequency distributions of unbinding forces between ICAM4 and αvβ3 in SS-RBCs for probes
coated with αvβ3 and then BSA and for probes coated only with BSA and not with αvβ3. (B) Boxwhisker plots showing the CF of active ICAM-4 receptors on SS-RBCs from probes coated with
αvβ3 and then BSA and for probes coated only with BSA and not with αvβ3 (p=0.0001).

2.A.4. AFM experiments on the same samples as the confocal microscopy experiments

Figure 2.A.4. SMFS adhesion results on the same samples as the confocal microscopy
experiments. CF of the unbinding events at baseline and after treatment with epinephrine for the
samples that were used in the confocal experiments shown in Figure 2.4. We found no significant
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difference in CF between WT- and SS-RBCs at the baseline and between WT and SS-RBCs after
treatment with epinephrine. We found significant difference in CF between WT-RBCs at baseline
and after treatment with epinephrine and between SS-RBCs at baseline and after treatment with
epinephrine. The results are in agreement with the results from the confocal experiments performed
on the same samples. (* signifies p < 0.04).

2.6. Appendix 2.B Measurements of Hydrodynamic drag force Fh on AFM cantilevers

This appendix is from the Supporting information of the paper: Maciaszek, J. L., K. Partola, J.
Zhang, B. Andemariam, and G. Lykotrafitis. 2014. Single-cell force spectroscopy as a technique
to quantify human red blood cell adhesion to subendothelial laminin. Journal of Biomechanics
47(16):3855-3861.

Fresh, ethanol cleaned, previously non-functionalized cantilevers were displaced through
Alsever’s solution and pressed onto a clean glass surface at eight different constant speeds:
0.5μm/s, 0.8μm/s, 1.0 μm/s, 2.0 μm/s, 4.0 μm/s, 6.0 μm/s, 8.0 μm/s, and 10.0 μm/s. Ten sets of
extension and retraction curves were obtained for each speed. Two types of cantilevers and five
cantilevers per type were tested. The first cantilever type tested was a tipless silicon nitride
cantilever with nominal spring constant of 80pN/nm and the second cantilever type tested was a
silicon nitride cantilever with a pyramidal tip and a nominal spring constant of 30pN/nm. For
each test, the cantilever was set to dwell for five seconds at the end of every approachretraction cycle in order to allow the cantilever to reach equilibrium before the new
measurement cycle. The difference between the average resistance forces during approach and
retraction corresponds to 2Fh, where Fh is the hydrodynamic drag force (217). Figure 2.B.1 A
shows a characteristic approach-retraction recording of a tipless cantilever at the speed of 0.8
μm/s. The difference between the recorded forces during the motion within the fluid is evident.
Figure 2.B.1 B shows the measured hydrodynamic forces for the two types of cantilevers at the
tested speeds. Table 2.B.1 gives the average recorded hydrodynamic forces for each case. At
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0.8 μm/s, where all our adhesion experiments were performed, the hydrodynamic forces were
approximately 4.33 pN for the tipless cantilever which was used for the SCFS experiments and
3.0 pN for the cantilever with a tip that was used for the SMFS experiments. In both cases, the
hydrodynamic forces are small compared to the measured unbinding forces. The unbinding
forces were quantified as the abrupt change with respect to the retraction curve.

Table 2.B.1. The speeds of the cantilevers and the corresponding average hydrodynamic drag
forces
Tipless cantilever (80 pN/nm)
Speed (μm/s)

0.5

0.8

1

2

4

6

8

10

Drag force (pN)

4.14

4.33

5.06

9.286

18.32

27.20

36.41

45.96

Cantilever with tip (30 pN/nm)
Speed (μm/s)

0.5

0.8

1

2

4

6

8

10

Drag force (pN)

2.82

2.99

3.50

6.04

11.14

17.09

21.90

28.08

Figure 2.B.1. Hydrodynamic drag forces on the AFM cantilevers. (A) A characteristic
approach-retraction curve recorded during the motion at a constant speed of 0.8 μm/s of a
tipless cantilever with a nominal stiffness of 80 pN/nm. (B) Variation of the hydrodynamic forces
applied during the motion in Alsever's solution of a tipless cantilever and a cantilever with a tip
at various constant speeds.
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Chapter 3. Valsartan Impedes Epinephrine-induced ICAM-4 Activation on Normal,
Sickle Cell Trait and Sickle Cell Disease Red Blood Cells

3.1. Introduction

In sickle cell disease (SCD), an inherited β-globin gene point mutation encodes abnormal
hemoglobin (HbS), which under deoxygenated conditions polymerizes to form long stiff filaments
deforming red blood cells (RBCs) from a biconcave to a sickle shape (60-62). Sickle cell trait (SCT)
is a heterozygous state characterized by the presence of both normal hemoglobin (HbA) and HbS.
While patients with SCD suffer increased mortality and often widespread chronic organ damage,
individuals with SCT are generally asymptomatic and live a normal lifespan. However, under
extreme conditions, such as hypoxia, acidosis, and dehydration, individuals with SCT can develop
a syndrome resembling SCD with vaso-occlusive sequelae (119, 120).

It has been shown that sickle RBCs (SS-RBCs) are stiffer and more viscous than normal (wildtype, WT) RBCs (63, 167, 172, 173, 218, 219). In addition, SCT-RBCs and SCD-RBCs are more
adhesive than WT-RBCs due to higher activation of surface receptors (64-67). Increased RBC
adhesion, enhanced stiffness, and abnormal shape contribute to the entrapment of RBCs in the
blood vessels and impediment of blood flow triggering painful vaso-occlusive episodes (VOEs),
the hallmark of SCD (74).

Human red blood cells (RBCs) express a large number of adhesion receptors on their membrane
such as basal cell adhesion molecule/Lutheran (BCAM/Lu) and intercellular adhesion molecule4 (ICAM-4), both of which are known to play a significant role in the genesis of vaso-occlusion in
SCD (66, 74, 171, 172, 174, 220, 221). BCAM/Lu and ICAM-4 bind with high affinity specifically
to laminin-α-5, a component of the endothelial subcellular matrix, and to endothelial integrin αvβ3
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respectively, and are the primary receptors that mediate the adhesion of SS-RBCs to endothelium.
Surface receptors can be activated through certain intracellular signal pathways (171, 172, 174,
181, 222). Previous research shows that BCAM/Lu and ICAM-4 receptor activation is mediated
via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) pathway (66, 172, 174,
223). As shown in Figure 3.1, stimulation of β2-adrenergic receptors (β2-ARs) with an agonist,
such as epinephrine, a catecholamine commonly secreted due to physical stress, can cause
dissociation of the alpha subunit of its coupled Gs protein, which then activates adenylyl cyclase
(AC) (181-184). AC catalyzes the conversion of adenosine triphosphate (ATP) to cAMP which
then activates PKA (172, 185). A kinase anchoring proteins (AKAPs) anchor PKA to specific
intracellular sites on the RBC membrane where PKA can alter the phosphorylation state of
neighboring RBC adhesion receptors thereby causing their activation (172, 223). Propranolol, as
a β-AR antagonist, has been shown to be effective in vivo both in mice and in humans to reduce
epinephrine-stimulated SS-RBC adhesion and to prevent vaso-occlusion in mice (105). These
findings suggest that RBC receptor blockers may have a role as anti-adhesive therapy for SCD.

Figure 3.1. RBC cAMP-PKA-dependent pathway and AT1R vs β-AR dimer/complex.
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The adrenergic system and the renin-angiotensin system are interrelated (Figure 3.1) (224).
Angiotensin II (Ang II) is an octapeptide hormone and neurotransmitter that plays a significant
role in the regulation of renal, cardiovascular, and endocrine function (225). Ang II exerts its
biological effects through signaling pathways activated upon binding to two receptors, Ang II type
1 receptor (AT1R) and Ang II type 2 receptor (AT2R), and relying mainly on binding to AT1R (226).
AT1R, similarly to β2-AR, is a member of the seven-transmembrane-domain, the superfamily of
G protein-coupled receptors (GPCRs), and it mediates most of the pathophysiological effects of
Ang II, including vasoconstriction, inflammation, growth, and fibrosis. Ang II binding to the AT1R
results in coupling of G proteins (Gq/G11and/or Gi/Go, G12, and G13) to the C-terminus of the
receptor and to stimulation of several intracellular/cytoplasmic signaling pathways (226-229).
Although receptors in the GPCR superfamily were initially believed to function as monomeric
entities, mounting evidence suggests that they are oligomers and function either through
interactions with identical units (homodimers) or with other GPCRs (heterodimers) (230-235). In
addition, many identified homodimers and heterodimers of GPCRs have different ligand binding
(236, 237), signaling (238, 239) and trafficking (240) properties from their constituent monomers.

Valsartan is an AT1R antagonist developed clinically for the treatment of hypertension and
congestive heart failure. It has been found that it reduces the risk of death after myocardial
infarction. Barki-Harrington et al (231) showed the existence of direct cross-talk between AT1R
and β-AR at the receptor level in human embryonic kidney (HEK) cells, mouse cardiomyocytes,
and COS-7 cell lines. They found that a single receptor antagonist blocks downstream signaling
of both AT1R and β-AR simultaneously. In particular, AT1R antagonist valsartan not only
attenuated the activation of its corresponding receptor AT1R but also inhibited β2-AR activity and
isoproterenol-mediated (ISO, β-AR agonist) generation of the second messenger cAMP. Similarly,
the non-selective β-blocker propranolol not only blocked the activation of β2-AR via epinephrine
but also inhibited the AT1R-mediated contractile response. In addition, the ability of the antagonist
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to inhibit receptor signaling was primarily dependent on the expression levels of both receptors.
Specifically, they showed that valsartan transinhibited β-ARs by functionally uncoupling β-AR
from its associated Gs protein and interrupted its downstream signaling pathway. Further, their
findings from differential epitope tagging and selective coimmunoprecipitation suggested that β2AR and AT1R were assembled as oligomers on the plasma membrane (Figure 3.1). Thus, the
trans-inhibition effect most likely worked on the β2-AR and AT1R constitutive complex formed on
the cell membrane. However, it is not known if this cross-talk between β-AR and AT1R is active
in RBCs.

In this study, we investigated the influence of valsartan on the cAMP-PKA pathway by measuring
the surface expression of active ICAM-4 receptors on human WT-, SCT-, and SS-RBCs. We
employed an atomic force microscopy (AFM) technique called single molecule force spectroscopy
(SMFS) (172) which can detect single functional receptors on RBCs as well as measure the
unbinding force between a receptor and its corresponding ligand (192-195, 197, 198, 223). We
demonstrated that pretreatment of RBCs with valsartan significantly hindered the activation of
ICAM-4 receptors induced by epinephrine. The findings of this work suggest that administration
of valsartan offers a possible way to mitigate vaso-occlusive episodes in SCD.

3.2. Materials and methods

Human subjects, blood collection and preparation

This study was approved by the Institutional Review Boards of the University of ConnecticutStorrs and UCONN-Health. All subjects were at least 7 years old and were ineligible to participate
if they were pregnant, breastfeeding, or within 3 months postpartum; used anti-lipid therapy within
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the previous week; were taking an investigational drug; or received a blood transfusion within the
previous 3 months. Additionally, homozygous SCD (SS) patients were only eligible to participate
if they were at steady state. Steady state was defined as having not received a parenteral opioid
in the previous 4 weeks, no pain greater than the usual daily level for 4 weeks, and no increase
in usual non-parenteral opioid medication in the previous 4 weeks. Hydroxyurea (HU) treatment
was an exclusion criterion because HU is known to inhibit BCAM/Lu adhesion to laminin (172,
199) and we inferred that HU might act in a similar way inhibiting activation of ICAM-4. Subject
demographic and clinical characteristics are provided in Table 3.1.

Table 3.1. Subject demographic and clinical characteristics

Subject numbers
Age, mean, SD
Gender, n, %
Race, n, %

Hemoglobin, g/dL,
mean, SD
Leukocyte count,
K/μL, mean, SD
Platelet, K/μL,
mean, SD
Neutrophil, %,
mean, SD
Reticulocytes, %,
mean, SD
LDH, U/L,
mean, SD

WT

SCT

SS

5
42 (14)

3
34 (5)

6
27 (5)

female 3 (60)
male 2 (40)
AfricanAmerican 4 (80)
White 1 (20)

female 3 (100)
AfricanAmerican 2 (67)
Latino 1 (33)

male 5 (83)
female 1 (17)
AfricanAmerican 6 (100)

14 (1)

13 (1)

9 (1)

7 (2)

6 (1)

12 (2)

222 (37)

228 (29)

430 (156)

47 (15)

58 (10)

58 (10)

N/A

N/A

13 (4)

N/A

N/A

497 (82)
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Blood samples of eligible subjects were collected into heparinized tubes. Whole blood was
centrifuged at 500 ×g for 5 min at 4℃ to isolate the RBCs. The plasma and buffy coat were
removed. The remaining RBCs were washed three times with Alsever’s solution and stored at 4℃
for up to 7 days. During experiments, RBCs were seeded in a glass bottom petri dish coated with
1 mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO). At this concentration, the RBCs
were immobilized while maintaining their original biconcave shape. All experiments were
performed under normoxic conditions. The reason is that hypoxia and the consequent changes
in the viscoelastic properties of SS-RBCs may play a role in the events of RBC adhesion and
would add an unwanted level of complexity to this work whose focus is the β-AR and AT1R crossregulation. In our experiments, we chose to test only RBCs that had the characteristic biconcave
shape to avoid reticulocytes, which generally have irregular shapes in our samples as tested in
our previous work (223).

Reagents

Human integrin αvβ3 protein (100 μg/mL, diluted in PBS) was purchased from Millipore (Billerica,
MA). Alsever’s solution, epinephrine (16.39 nM, reconstituted in Alsever’s solution), valsartan (2
μg/mL, reconstituted in DMSO), and bovine serum albumin (BSA; 100 μg/mL, reconstituted in
PBS) were purchased from Sigma-Aldrich (St. Louis, MO). RBCs were treated with the reagents
at 37℃ for 30 min. We note that the peak value of plasma valsartan concentration after a single
80 -160 milligrams oral dose administration of clinical valsartan tablet was approximately 2 μg/mL
(241, 242). Also, the maximum daily valsartan dose for adults is 320 mg, and the peak plasma
concentration was measured to be 5.5 μg/mL (243). Testing the effects of valsartan at different
concentrations on SS-RBC ICAM-4 expression using SMFS, we found that there was no
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significant difference between the effect of valsartan at 1, 2, and 10 μg/mL (the corresponding
active ICAM-4 densities were 11.46 ± 1.18%, 8.77 ± 1.58%, and 7.32 ± 1.32%). Based on these
results, which cover the entire spectrum of clinical valsartan dose administration, we decided to
use 2 μg/mL in our experiment, which is close to the peak plasma concentration resulted from the
recommended starting dose.

AFM probe functionalization

Silicon nitride AFM probes were purchased from Bruker Nano Inc. (Camarillo, CA). The tip height
was 2.5 - 8 μm and the nominal tip radius was 20 nm. The nominal spring constant of the applied
cantilever is 30 pN/nm. The actual spring constant under the experimental condition (in Alsever’s
solution at 37℃) was computed using a thermal noise collecting method (202, 203). The
cantilevers were first soaked in 2% v/v 3-aminopropyltriethoxysilane (APTES) in acetone (SigmaAldrich, St. Louis, MO) for 10 min, then rinsed with deionized (DI) water. Cantilevers were treated
with 0.5% v/v glutaraldehyde (solution in DI water) for 30 min to adhere the glutaraldehyde
molecule linker, then rinsed again with DI water and incubated in 100 μg/mL αvβ3 solution to
attach the ligand. After 30 min, the cantilevers were rinsed again with DI water and immersed in
100 μg/mL BSA for 1 min to block the residual aldehyde groups. Cantilevers were stored in PBS
at 4℃ and used within three days.
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AFM setup

All experiments were performed using the MFP-3D-BIO AFM (Asylum Research, Santa Barbara,
CA), which was mounted on an inverted microscope (Zeiss Axiovert A1, Oberkochen, Germany).
The microscope gave a clear image of RBCs, which were seeded in a transparent glass bottom
petri dish allowing us to choose RBCs that were less than 10 μm in diameter and maintained a
distinct circular biconcave shape. For each experimental condition, 5 RBCs were tested from each
subject. A schematic of a functionalized AFM probe scanning the membrane of a RBC is shown
in Figure 3.2 A.

Figure 3.2. Schematic of a SMFS experiment along with a representative forcedisplacement measurement and the corresponding histogram. (A) AFM probing illustration.
The yellow colored element represents the glutaraldehyde linker and the ligand αvβ3 protein
molecule attached to the cantilever tip. (B) Representative force-displacement curve. The red
curve denotes approach and the blue curve denotes retraction. (C) Frequency distributions of
unbinding forces between ICAM-4 and αvβ3 in WT-, SCT-, and SS-RBCs.

Force-distance curves were recorded at 32×32 points as the cantilever scanned over a 1μm2 area
of the RBC surface. Each curve contained a full approach and retraction trace (as shown in Figure
3.2 B). We have shown that 1 μm2 scanning area for SMFS experiments on RBCs gives a
representative result for the specific tested RBC (167). When unbinding events occurred between
the αvβ3-functionalized cantilever and ICAM-4 receptors expressed on the RBC membrane, an
54

unbinding force was displayed as the cantilever was retracted from the cell surface (172, 223).
The unbinding force was measured as the magnitude of the abrupt drop to zero of the retraction
force-displacement curve (Figure 3.2 B). All data were processed using our in-house developed
code named FRAME (Force Review Automation Environment) (204).

The cantilever approach/retraction speed was held constant at 800 nm/s, which corresponds to a
nominal loading rate of 24,000 pN/s. At this speed, the force measurements were not significantly
affected by hydrodynamic drag (Figure 3.2 B) as it is clear from the overlapping between the
approach and retraction curves before and after contact with the RBC membrane (205). We only
considered the unbinding events for which the effective spring constants (Keff) were less than 10
pN/nm which, in combination with the cantilever moving speed, ensures that the influence of Keff
on the magnitude of the unbinding force for the specific loading rate is not significant for SMFS
experiments (206). The effective spring constants were calculated from the slopes of the curves
adjacent to the unbinding force drops (207, 208). A specific threshold was set to control the
indentation depth and to apply the same nominal maximum force to each RBC. The probe traveled
a distance of ~200 nm, which corresponded to a contact time between the probe and the RBC
membrane of ~1/4 s before retraction.

To illustrate the population of the active ICAM-4 receptors on the RBC surface, the collective
frequencies were showed in box-and-whisker plots. Collective frequency (CF, %) was defined as
the percentage of all unbinding events with respect to the total number of measurements
(32×32=1024 for each cell). The CF revealed the percentage of active ICAM-4 receptors that
were able to bind to αvβ3. This approach allowed the observation of the modulation of the CF of
activated ICAM-4 receptors in the presence of valsartan and the other biochemical reagents.
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Statistical methods

The unbinding forces between αvβ3 ligands and ICAM-4 receptors are reported using frequency
(%) distribution which states the percentage of events whose corresponding unbinding forces
were within each bin's width (Figure 3.2 C). The CF results are reported as mean ± standard error
(SE) and illustrated by box-and-whisker plots (GraphPad Prism, GraphPad Software, Inc., La Jolla,
CA). Significance was determined using one-way analysis of variance (ANOVA). The results were
considered significant if p<0.05.

3.3. Results and discussion

First, we verified previous findings that epinephrine stimulates the activation of ICAM-4 receptors
on WT-, SCT- and SS-RBCs (173, 223). Epinephrine, as a catecholamine, acts on β-ARs and
stimulates the cAMP- PKA-dependent signaling pathway. The purpose of these experiments was
to exclude the variance due to different blood samples and only compare the variation of active
ICAM-4 receptors caused by the different reagents that we used. We employed the SMFS assay
to scan a 1 μm × 1 μm membrane areas of individual RBCs with an AFM cantilever functionalized
with αvβ3 to detect variation of active ICAM-4 receptors and measure the unbinding forces
between active ICAM-4 and αvβ3 under different experimental conditions.

Treatment with epinephrine caused a significant increase in the CF of active ICAM-4 receptors
on the surface membrane of WT-RBCs from 8.98 ± 1.20% at baseline to 17.00 ± 1.89% (p=0.0003;
Figure 3.3 A, Table 3.2). The CF of active ICAM-4 receptors of SCT-RBCs was measured to be
5.58 ± 0.76% at baseline, which is similar to the CF obtained for WT-RBCs (p=0.4696). Treatment
of SCT-RBCs with epinephrine significantly increased the CF of active ICAM-4 receptors to 17.11
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± 1.50% (p<0.0001; Figure 3.3 B, Table 3.2). The CF of active ICAM-4 adhesion was 11.68 ±
1.68% for SS-RBCs at baseline, which is higher than that measured for WT- and SCT-RBCs, but
not significantly (p=0.9999, 0.1768). Similar to the observations made in WT- and SCT-RBCs,
SS-RBCs treated with epinephrine demonstrated significantly higher CF of active ICAM-4
receptors 20.58 ± 2.76% (p=0.0019; Figure 3.3 C, Table 3.2) compared to baseline.
Table 3.2. Collective frequencies of active ICAM-4 receptors for WT-, SCT- and SS-RBCs
Collective frequency (mean ± SE, %)
WT
SCT
SS
Test condition
Baseline
+epinephrine
+valsartan
+valsartan +epinephrine

8.98 ± 1.20
17.00 ± 1.89
5.20 ± 0.57
10.41 ± 1.35

5.58 ± 0.76
17.11 ± 1.50
3.13 ± 0.22
6.87 ± 0.91

11.68 ± 1.68
20.58 ± 2.76
6.41 ± 0.91
10.07 ± 1.02

Figure 3.3. Box-and-whisker plots of the CF of active ICAM-4 receptors on (A) WT-RBCs,
(B) SCT-RBCs, (C) SS-RBCs. Data are shown as the median with minimum and maximum
whiskers, and the mean is denoted as a color dot. Significance between conditions is denoted
as * such that p<0.05. The n on the x-axis indicates the total number of mature RBCs tested in
each group: WT-RBC: 5 subjects; SCT-RBC: 3 subjects; SS-RBC: 6 subjects.

Valsartan suppresses the activation of ICAM-4 receptors induced by epinephrine
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Valsartan is an AT1R blocker and a common clinical drug for treatment of hypertension and heart
failure. In addition, it has been demonstrated that in cardiomyocytes, HEK 239 and COS-7 cells
valsartan can simultaneously block downstream signaling of both AT1R and β-AR by affecting
AT1R and β-AR heterodimers by diminishing the coupling between a β-AR and its corresponding
Gs protein (231). In this work, we investigated if treatment of RBCs with valsartan would affect
the CF of active ICAM-4 receptors expressed on the surface membrane of the RBCs. We found
that valsartan-treated WT-RBCs exhibited similar CF of active ICAM-4 to untreated WT-RBCs
(5.20 ± 0.57% vs. 8.98 ± 1.20%, p=0.2178; Figure 3.3 A; Table 3.2), but significantly lower CF of
active ICAM-4 than epinephrine-treated WT-RBCs (5.20 ± 0.57% vs. 17.00 ± 1.89%, p<0.0001;
Figure 3.3 A; Table 3.2). Then, we investigated if valsartan affects epinephrine stimulation of
active ICAM-4 adhesion receptors. To this end, we sequentially incubated WT-RBCs with first
valsartan and then epinephrine and compared their combined effect on the CF of ICAM-4
receptors with that of epinephrine exposure alone. We demonstrated that pre-treatment with
valsartan resulted in a significant decrease in the expected epinephrine-induced activation of
ICAM-4 adhesion receptors (10.41 ± 1.35% vs. 17.00 ± 1.89%, p=0.0045, Figure 3.3 A; Table
3.2).

Similar experiments were performed on SCT-RBCs. As with WT-RBCs, SCT-RBCs showed no
distinct change in the CF of active ICAM-4 when RBCs treated only with valsartan (3.13 ± 0.22%
vs. 5.58 ± 0.76%, p=0.2497, Figure 3.3 B; Table 3.2). However, when SCT-RBCs were treated
with valsartan prior to their exposure to epinephrine, the CF of ICAM-4 receptors was significantly
lower compared to treatment with only epinephrine (6.87 ± 0.91% vs. 17.11 ± 1.50%, p<0.0001,
Figure 3.3 B; Table 3.2).

The same experiments were then performed on SS-RBCs. Similarly to WT-RBCs and SCT-RBCs,
SS-RBCs exhibited a comparable level of active ICAM-4 to baseline SS-RBCs with valsartan

58

treatment alone (6.41 ± 0.91% vs. 11.68 ± 1.68%, p=0.1195, Figure 3.3 C; Table 3.2), but showed
a significant decrease with valsartan prior to epinephrine treatment compared to treatment with
only epinephrine (10.07 ± 1.02% vs. 20.58 ± 2.76%, p=0.0004, Figure 3.3 C; Table 3.2).

At baseline, WT-, SCT- and SS-RBCs demonstrated similar unbinding forces between the αvβ3
ligand and ICAM-4 (Figure 3.3.2 C). In addition, neither epinephrine nor valsartan altered the
unbinding force level between the αvβ3 ligand and ICAM-4 receptor, suggesting the reagents
affect only the activation of ICAM-4 receptors and not the strength of their interactions with αvβ3.

AT1R blockade significantly decreased the epinephrine-induced increase in the CF of active
ICAM-4 adhesion receptors in WT-, SCT- and SS-RBCs. These findings suggest that valsartan
efficiently suppressed the effect of epinephrine on the activation of ICAM-4 receptors in WT-,
SCT-, and SS-RBCs. As postulated in previous research (231), β-AR and AT1R may form a
constitutive complex on the RBC membrane. Administration of valsartan could act on the complex,
not only blocking the action of AT1R but also uncoupling the β-AR and its cognate Gs protein. In
this case, epinephrine could no longer effectively stimulate β-AR and the following cAMP-PKAdependent pathway through Gsα dissociation. The nature of the uncoupling effect may involve a
conformational change on β-AR making it no longer favorable to bind to Gs protein which is
currently under investigation (231, 244).

3.4. Conclusions

In this study, we explored the effect of valsartan on the activation of ICAM-4 receptors on WT-,
SCT- and SS-RBCs. We observed that epinephrine significantly increased the surface percentage
of active ICAM-4 receptors on WT-, SCT- and SS-RBCs. Importantly, we showed that although
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exposure to valsartan alone did not have a significant effect on basal level adhesion, pretreatment of RBCs with valsartan prior to epinephrine stimulation resulted in a significant decrease
in the percentage of active ICAM-4 receptors compared to treatment with only epinephrine. This
may have major clinical implications as our data suggest that valsartan can modulate SS-RBCs
adhesion, which is a known contributor to vaso-occlusion. Our findings suggest that administration
of valsartan could mitigate the vaso-occlusive consequences of SCD and may open new avenues
for the development of novel therapeutic targets.
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Chapter 4. Influence of Clinical Chemotherapeutic Agents on the Activation of
RBC ICAM-4 Adhesion Receptors Varies Due to Race and SCT Carrying Status

4.1. Introduction

African-Americans have worse cancer survival prognosis compared to whites (245, 246),
particularly among female breast cancer patients. This cannot be fully explained by either socioeconomic or tumor marker expression differences (246-248). Although mortality from breast
cancer has been falling for white women in recent years across the United States, the death rate
for African-Americans has declined more slowly resulting in a growing disparity (246). It has been
long-recognized that African-American women with breast cancer have lower survival probability
compared to women of European ancestry in nearly all states in the United States (249, 250).
This disparity is particularly perplexing given that the incidence of breast cancer has been
consistently lower in African-Americans. African-Americans also experience higher rates of
adverse events during systemically administered cancer chemotherapy (251). A survival disparity
was observed in a pooled analysis of clinical trial conducted by the southwest oncology group
(SWOG), when patients received uniform treatment, suggesting that inherited host factors might
contribute to disparate cancer-treatment outcomes (252). An unstudied genetic trait in cancer
outcomes are hemoglobinopathies, particularly sickle cell trait (SCT) which is estimated to occur
in 8 -10% of African-Americans but in only ~0.001% of white Americans of European ancestry
(253).

People with SCT carry both normal and abnormal version of the Hemoglobin gene (i.e., HbAS),
which is responsible for expression of the β-chain of hemoglobin. There have been reports
describing chemotherapy-induced intravascular sickling including those known as SCT carriers
and have been asymptomatic previously (175, 254-256). Subsequent vaso-occlusion (overt or
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sub-clinical) may give rise to symptoms such as pain and nausea, or clinical signs such as
unexplained anemia and renal insufficiency. These signs and symptoms may lead to treatment
delays, dose-reductions and in some cases, cessation of therapy, all of which can impact efficacy
and, most importantly, survival. Sickling crises were also reported in patients with SCT undergoing
chemotherapy for cervical cancer (257).

Current research suggests that vaso-occlusion in SCD are, in part, due to complex intravascular
hetero-cellular interactions between RBCs, leukocytes and endothelial cells (ECs) that lead to
microvascular obstruction, distal ischemia and resultant organ damage (175, 254, 258-260).
Several receptor-ligand interactions have been shown to be critical to SCD RBC-EC adhesion
including BCAM/Lu – laminin (128), and ICAM-4 – αvβ3 (261). Our group has focused on defining
the signaling pathways associated with enhanced RBC adhesion in SCD (172, 205, 223). If we
could show a correlation between SCT and the genesis of vaso-occlusive complications in cancer
treatment, we may expand current knowledge of potentially modifiable biologic differences
between whites and blacks narrowing the gap in cancer treatment outcomes.

The identification of biological reasons for cancer survival disparities between blacks and whites
is in critical need. To our knowledge, we are the first to explore enhanced RBC adhesion as a
potential etiology for disparate survival among black women with breast cancer. By applying
single molecule-AFM technique, we were able to measure the adhesion between ICAM-4
receptors on RBC with endothelial αvβ3 integrins attached to the AFM cantilever tip. This may set
the basis for the future clinical procedure, running SCT carrier screening prior to chemotherapy
treatment in order to optimize therapeutic approaches and potentially improve patient outcomes.

We measured the number of active ICAM-4 adhesion receptors on RBCs from three groups of
participants: white female with wild-type hemoglobin (WFWT), black female with wild-type
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hemoglobin (BFWT), and black female sickle cell trait (BFSCT) with and without the administration
of two chemotherapeutic agents, cyclophosphamide (CYP) and daunorubicin (DNR). We found
that both drugs did not affect the ICAM-4 expression on WFWT-RBCs. CYP increased the ICAM4 expression on BFWT-RBCs. DNR increased the ICAM-4 expression on BFSCT-RBCs. The
findings suggest race and SCT carrying status might be crucial factors in choosing chemotherapy
regimens for different patients.

4.2. Materials and methods

Human subjects, blood collection and preparation

This study was approved by the Institutional Review Boards of the University of ConnecticutStorrs and UCONN-Health. The target population included healthy female volunteers with and
without SCT. Healthy volunteers (with or without known SCT) were eligible if they are at least 18
years old and do not self-identify as having SCD and were excluded if they are pregnant, breastfeeding, within 3 months post-partum, have received a blood transfusion within the preceding 3
months, are taking prescription medication or an investigational drug, or have had surgery within
the previous 6 weeks. We enrolled three groups of healthy study participants: black females with
wild-type hemoglobin (BFWT), white females with wild-type hemoglobin (WFWT), and black
female sickle cell trait carriers (BFSCT). Subject demographic and clinical characteristics are
provided in Table 4.1.
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Table 4.1. Subject demographic and clinical characteristics

Subject numbers
Age, mean, SD
Gender, n, %
Race, n, %
Hemoglobin, g/dL,
mean, SD
Leukocyte count,
K/μL, mean, SD
Platelet, K/μL,
mean, SD
Neutrophil, %,
mean, SD

BFWT

WFWT

BFSCT

3
42 (6)

3
52 (14)

4
34 (5)

female 3 (100)

female 3 (100)

female 4 (100)

AfricanAmerican 3 (100)

White 3 (100)

AfricanAmerican 4 (100)

13 (1)

14 (1)

13 (1)

7(2)

4 (0)

6 (1)

246 (63)

245 (40)

228 (29)

53 (17)

43 (4)

58 (10)

Blood samples of eligible subjects were collected into heparinized tubes after obtaining informed
consent. Whole blood was centrifuged at 500 ×g for 5 min at 4℃ to isolate the RBCs. The plasma
and buffy coat were then removed. The remaining RBCs were washed three times with Alsever’s
solution and stored at 4℃ and used within 7 days. To immobilize the RBCs in the meantime to
maintain their biconcave shape, they were seeded in a glass bottom petri dish pretreated with 1
mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 15 min. All measurements were
obtained under normoxic conditions because hypoxia may introduce a syndrome resembling
sickle cell disease (SCD) in sickle cell trait (SCT)-RBCs with sickling and enhanced adhesiveness.

Ligand and drugs

Human integrin αvβ3 protein (100 mg/mL, diluted with PBS) was obtained from Millipore (Billerica,
MA). Alsever’s solution, Cyclophosphamide (CYP, 80.335 μM, reconstituted in DMSO),
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Daunorubicin (DNR; 57.988 μM, reconstituted in DMSO), and bovine serum albumin (BSA; 100
mg/mL, reconstituted in PBS) were purchased from Sigma-Aldrich (St. Louis, MO). RBCs were
treated with the above-mentioned drugs at 37 ℃ for 30 min.

AFM cantilever probe functionalization

Soft silicon nitride cantilevers with silicon nitride tips were purchased from Bruker Nano (Camarillo,
CA). The tip height was between 2.5 and 8 mm and the nominal tip radius was 20 nm. The nominal
spring constant of the applied cantilever was 30 pN/nm. The actual spring constant under the
experimental condition (in Alsever’s solution at 37 ℃) was calculated via a thermal-noise-based
method.

Silicon

nitride

probes

were

first

amino-functionalized

with

2%

v/v

3-

aminopropyltriethoxysilane in acetone (Sigma-Aldrich) for 10 min and then rinsed with deionized
(DI) water. The probes were soaked in 0.5% v/v glutaraldehyde (solution in DI water) for 30 min,
rinsed again with DI water, and incubated in a 100 mg/mL αvβ3 solution. After 30 min, the probes
were rinsed with DI water and immersed in 100 mg/mL of BSA for 1 min to block the remaining
aldehyde groups. The probes were stored in PBS at 4℃ and used within 3 days.

Statistical analysis

The unbinding forces between αvβ3 ligands and intercellular adhesion molecule-4 (ICAM-4)
receptors are reported using the frequency (%) distribution, which states the percentage of events
whose unbinding forces are within each bin’s width. We then compared the median values of the
forces measured in experiments without and with treatment with different drugs. The zero force
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points are not shown because they would obscure the plots since their population is much larger
than the population of unbinding events. The collective frequency (CF, %) is related to the
population of active ICAM-4 receptors and is defined as the percentage of all unbinding events
divided by the total number of measurements, which is 32 × 32 =1024 for each cell multiplied by
the number of tested cells for each blood sample. The CF results are reported as the mean ±
standard error (SE) and illustrated by box-and-whisker plots (GraphPad Prism, GraphPad
Software, San Diego, CA). Statistical significance was determined by one-way analysis of
variance (ANOVA) and the Tukey-Kramer post hoc test. The results are considered significant if
p < 0.05.

4.3. Results and discussion

We first measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3 and
ICAM-4 on black female normal RBCs (BFWT-RBCs) with and without CYP and DNR treatment.
The CF of active ICAM-4 receptors was measured to be 6.82 ± 1.30% for BFWT-RBCs at baseline
(without treatment). Treatment of BFWT-RBCs with CYP significantly increased the CF of active
ICAM-4 receptors to 15.72 ± 1.91% (p=0.0001; Figure 4.1, Table 4.2). Treatment of BFWT-RBCs
with DNR held the CF of active ICAM-4 receptors at similar level 7.79 ± 0.78% (p=0.8794; Figure
4.1, Table 4.2) as the baseline value. There was also a significant difference in the number of
active ICAM-4 adhesion receptors between CYP treated and DNR treated BFWT-RBCs
(p=0.0008, Figure 4.1).
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Figure 4.1. BFWT-RBC ICAM-4 expression with and without CYP and DNR treatments.
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in BFWT-RBCs. (B)
Box-and-whisker plot of the CF of active ICAM-4 receptors on BFWT-RBCs. Data are shown
as the median with minimum and maximum whiskers, and the mean is denoted as a color dot.
Significance between conditions is denoted as * such that p<0.001. The ‘n’ on the x-axis
indicates the total number of RBCs analyzed in each condition, obtained from 3 subjects.

Table 4.2. Unbinding forces between ICAM-4 and αvβ3 and collective frequencies of active ICAM4 receptors for BFWT-, WFWT- and BFSCT-RBCs

Test
condition
Baseline
+CYP
+DNR

Unbinding force (median, pN)
BFWT
WFWT
BFSCT

Collective frequency (mean ± SE, %)
BFWT
WFWT
BFSCT

25.90
30.99
26.31

6.82 ± 1.30
15.72 ± 1.91
7.79 ± 0.78

26.05
26.47
28.27

26.99
25.71
34.15

9.54 ± 1.31
7.51 ± 1.48
7.47 ± 1.07

4.88 ± 0.87
6.59 ± 1.05
13.13 ± 2.30

Next, we measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3
and ICAM-4 on RBCs from white females with wild-type hemoglobin (WFWT-RBCs) with and
without CYP and DNR treatment. The CF of active ICAM-4 receptors was measured to be 9.54 ±
1.31% for WFWT-RBCs at baseline. Treatment of WFWT-RBCs with CYP and DNR both held the
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CF of active ICAM-4 receptors at the similar level as the untreated WFWT-RBCs (CYP: 7.51 ±
1.48%, p=0.514; DNR: 7.47 ± 1.07%, p=0.5012; Figure 4.2, Table 4.2). Also, there was no
significant difference in the number of active ICAM-4 adhesion receptors between CYP treated
and DNR treated WFWT-RBCs (p=0.9998, Figure 4.2).

Figure 4.2. WFWT-RBC ICAM-4 expression with and without CYP and DNR treatments.
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in WFWT-RBCs.
(B) Box-and-whisker plot of the CF of active ICAM-4 receptors on WFWT-RBCs. Data are
shown as the median with minimum and maximum whiskers, and the mean is denoted as a
color dot. The ‘n’ on the x-axis indicates the total number of RBCs analyzed in each condition,
obtained from 3 subjects.

Finally, we measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3
and ICAM-4 on RBCs from black females with sickle cell trait (BFSCT-RBCs) with and without
CYP and DNR treatment. The CF of active ICAM-4 receptors was measured to be 4.88 ± 0.87%
for BFSCT-RBCs at baseline. Treatment of BFSCT-RBCs with CYP held the CF of active ICAM4 receptors at similar level 6.59 ± 1.05% (p=0.7329; Figure 4.3, Table 4.2) as the baseline value.
Treatment of BFSCT-RBCs with DNR significantly increased the CF of active ICAM-4 receptors
to 13.13 ± 2.30% (p=0.00014; Figure 4.3, Table 4.2) compared to the baseline. In addition, there
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was a significant difference in the number of active ICAM-4 adhesion receptors between CYP
treated and DNR treated BFSCT-RBCs (p=0.013, Figure 4.3).

Figure 4.3. BFSCT-RBC ICAM-4 expression with and without CYP and DNR treatments.
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in BFSCT-RBCs.
(B) Box-and-whisker plot of the CF of active ICAM-4 receptors on BFSCT-RBCs. Data are
shown as the median with minimum and maximum whiskers, and the mean is denoted as a
color dot. Significance between conditions is denoted as * such that p<0.05. The ‘n’ on the xaxis indicates the total number of RBCs analyzed in each condition, obtained from 4 subjects.

In summary, our experiments showed that CYP significantly increased the activation of ICAM-4
receptors on BFWT-RBCs but not on WFWT-RBCs and BFSCT-RBCs; DNR significantly
increased the activation of ICAM-4 receptors on BFSCT-RBCs but not on BFWT-RBCs and
WFWT-RBCs. The findings indicated that the effect of chemotherapeutic agents on RBC ICAM4 expression varied due to race and SCT carrying status, suggesting they might be critical factors
in choosing chemotherapy regimens for different patients. SCT has been thought to have no
impact on survival in general. Hence, most adults with SCT and their care-providers, are not
aware of their SCT carrier status (262). Genetic screening for SCD/SCT status has only been
introduced as part of routine newborn screening nationally in the past two decades. However,
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there have been reports of patients with SCT undergoing chemotherapy developing sickle cell
crisis (122). In terms of the impact on survival, there are reports that African-American women
with breast cancer have higher rates of self-withdrawal from treatment even in national
cooperative trials, this might reflect, in part, some degree of adverse consequences related to
SCT interaction with chemotherapy. The finding of SCT being a clinically significant problem in
the context of chemotherapeutic treatment may lead to novel approaches to reverse disparities in
cancer treatment outcomes among African-Americans.
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Chapter 5. Further Approaches to Understand RBC Biophysics

5.1. AFM-based microrheology measures RBC viscoelastic properties

RBCs experience large deformation during microcirculation given that the diameter of the smallest
capillaries is only one-third of a normal RBC’s diameter (263). Changes in cell deformability, as
occur in SCD, have an essential role in microcirculatory dysfunction. To better understand how
mechanical stresses and deformations regulate cellular functions requires a detailed knowledge
of the mechanical properties of cells. Normal RBC deformability has been measured in terms of
the shear, bending, and area expansion moduli of the cell membrane using various techniques,
including micropipette aspiration, optical tweezers, and high-frequency electrical deformation
tests, which apply quasi-static loads and can achieve large deformations (264-270). Further, the
viscoelastic properties of the normal RBC in response to time-dependent loads were studied
through optical magnetic twisting cytometry, which applies a torque to a ferrimagnetic micro-bead
tightly bound to the cell surface (271). However, the bead binding positions were quite random
and hardly repeatable. In comparison, AFM provides a more efficient way to generate timedependent loadings, record RBC responses, and measure RBC viscoelasticity by calculating the
absolution value of the complex modulus, 𝐺 ∗ (𝜔). The tip at the end of a flexible cantilever is able
to locally indent the cell membrane with a precise control of the loading rate. 𝐺 ∗ (𝜔) is defined as
he complex ratio in the frequency domain between the applied stress and the resulting strain
(272). The real and imaginary parts of 𝐺 ∗ (𝜔) account for the storage modulus (elastic modulus)
𝐺 ′ and the loss modulus (frictional modulus) 𝐺 ″ respectively.
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When cells are exposed to sinusoidal oscillating, the strain is neither exactly in phase with the
stress (as it would be for a perfect elastic solid) nor 90° out of phase (as it would be for a perfect
viscous liquid) but is somewhere in between. This means cells are viscoelastic, exhibiting both
solid- and liquid-like characteristics. Cells store and dissipate mechanical energy and response
to mechanical stimuli depending on the rate at which the stimuli are applied (161, 271, 273).

Method described here (Figure 5.1, 5.2) may be applicable to characterize and connect the
mechanical and biological properties of the RBC in health and disease. It measured complex
modulus over various loading frequencies generated by an AFM with the corrections of system
lag and hydrodynamic viscous drag. The triangle cantilever with a tip was used to locally indent a
cell. The tip height was between 2.5 and 8 μm and the nominal tip radius was 20 nm. The nominal
resonant frequency of the cantilever was 15 kHz. The nominal spring constant of the applied
cantilever was 30 pN/nm. The actual spring constant (𝑘) under the experimental condition (in
Alsever’s solution at 37℃) was calculated by a thermal noise based method (202, 203). The
cantilever oscillated around the indentation depth 𝛿0 (~200nm, 10% of the thickness of an RBC)
with a 5 nm amplitude at different frequencies: 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz. There
were 12 cycles of sinusoidal oscillation at each frequency and 0.5s of resting time between
frequencies.
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Figure 5.1. Schematic illustration of a cantilever tip oscillates in contact with a cell.
Oscillation was controlled around the indentation depth δ0 with an amplitude δ𝜔 at the
frequency ω (273).

Figure 5.2. AFM generates time-dependent loadings. Time-dependent loading function (top)
and the corresponding force-time curve (bottom) obtained from an AFM tip indenting a normal
RBC. When the cantilever gets into contact with the cell, the force increases rapidly until the
given trigger point is reached. During dwell in contact, the cantilever is excited to sinusoidal
oscillations with frequencies 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz with the amplitude of 5
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nm, 12 cycles of each frequency and 0.5s of resting time between frequencies. Afterward, the
cantilever is retracted.

5.1.1 Correction of phase lag between excitation of the cantilever and the force response

First, the system lag (𝜑𝑙𝑎𝑔 ) between excitation of the cantilever (Z position) and the force response
in a viscous environment was tested for every frequency in each measurement. Zsensor-time and
force-time curves were recorded when ramping the Z position (displacement) with 5 nm amplitude
sinusoidal oscillations at different frequencies (5-200 Hz) and with tip-substrate in contact (Figure
5.3). Since the substrate was a hard glass surface, the deviation from 0° phase shift was
compensated.

Figure 5.3. Zsensor-time and force-time curves when ramping the AFM tip on a hard
substrate. Time-dependent loading function (top) and the corresponding force-time curve
(bottom) obtained from oscillating an AFM tip on a hard glass substrate. When the cantilever
gets into contact with the substrate, the force increases rapidly until the given trigger point is
reached. During dwell in contact, the cantilever is excited to sinusoidal oscillations with
frequencies 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz with the amplitude of 5 nm, 12 cycles of
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each frequency and 0.5s of resting time between frequencies. Afterward, the cantilever is
retracted.

5.1.2. Correction of hydrodynamic drag force

Force measurements with AFM in the liquid are subjected to the hydrodynamic drag force (𝐹ℎ )
due to viscous friction of the cantilever with the liquid. The effect of hydrodynamic drag is modeled
in Figure 5.4.

Figure 5.4. A mechanical model of the cantilever tip in contact with a soft sample in
liquid. The cantilever is represented by a 1-D oscillator with spring constant 𝑘 and effective
mass 𝑚𝑒𝑓𝑓 . The sample displacement is produced by the piezoactuator (274).

When testing a sample in liquid, the force exerted on the cantilever (𝐹) has two main components:
the force applied by the sample (𝐹𝑠 ) and the hydrodynamic drag force (𝐹ℎ ) applied by the liquid.
Common approaches estimate 𝐹ℎ at a certain distance above the sample and subtract its value
from the contact force measured on the sample. However, this procedure can underestimate 𝐹ℎ
at contact. Instead, drag forces of liquid on the cantilever can be measured in noncontact when
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ramping the Z position (displacement, see Figure 5.5) with low-amplitude (5 nm) sinusoidal
oscillations at different frequencies (𝜔, 5-200 Hz) and tip-substrate distances (ℎ, 0.25-4 μm). Then
drag factor at contact can be obtained by extrapolation.

Ⅰ

Ⅲ

Ⅱ

Figure 5.5. Z-displacement input function for calculating the hydrodynamic drag factor.
sectionⅠ: pull the tip away from glass substrate to a certain height (e.g. 250 nm); sectionⅡ:
rest a short time, 0.5s; section Ⅲ: oscillate the cantilever under 5, 10, 25, 50, 75, 100, 120,
150, 200 Hz with the amplitude of 5 nm, 12 cycles of each frequency and 0.5s of resting time
between frequencies.

The displacement of the piezo (𝑧) consists of the sample indentation (𝛿) and cantilever deflection
(𝑑) as shown in Figure 5.5. The relative velocity between the cantilever and the surface of the
sample is 𝑣 =

𝑑𝛿
.
𝑑𝑡

The variables 𝑧 and 𝑑 can be measured directly. Then, 𝐹 and 𝛿 can be

computed as 𝐹 = 𝑘𝑑 and 𝛿 = 𝑧 − 𝑑. The equation of motion of the cantilever is

𝑑2 𝑑

𝑚𝑒𝑓𝑓 𝑑𝑡 2 + 𝑘𝑑 = 𝐹𝑠 + 𝐹ℎ

(5.1)
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The microrheological behavior of the sample can be characterized in the frequency domain with
a mechanical transfer function defined as 𝐻𝑠 (𝜔) = 𝐹𝑠 (𝜔)/𝛿(𝜔), where 𝐹𝑠 (𝜔) and 𝛿(𝜔)are the
fourier transforms of 𝐹𝑠 and 𝛿, respectively, and 𝜔 is the oscillation frequency. 𝐻𝑠 (𝜔) is a complex
value for viscoelastic samples and is expected to show the same frequency dependence as the
complex modulus. Similarly, the viscoelastic behavior of the liquid is characterized by the
hydrodynamic drag transfer function defined as 𝐻ℎ (𝜔) = 𝐹ℎ (𝜔)/𝛿(𝜔). Transforming equation (5.1)
to the frequency domain and dividing by 𝛿(𝜔)

𝑑(𝜔)

(−4𝜋 2 𝑚𝑒𝑓𝑓 𝜔2 + 𝑘) 𝛿(𝜔) = 𝐻𝑠 (𝜔) + 𝐻ℎ (𝜔)

(5.2)

Solving equation (5.2) for 𝐻𝑠 (𝜔)

𝜔
𝜔0

𝐻𝑠 (𝜔) = [1 − ( )2 ]𝐻(𝜔) − 𝐻ℎ (𝜔)

(5.3)

Where 𝜔0 is the resonant frequency of the cantilever and 𝐻(𝜔) is the global mechanical transfer
function. At low frequencies (𝜔 ≪ 𝜔0 ) , equation (5.3) can be simplified as

𝐻𝑠 (𝜔) = 𝐻(𝜔) − 𝐻ℎ (𝜔)

(5.4)

In low Reynolds number conditions (Re < 1), the hydrodynamic drag force is expressed as below
and increases proportionally with the relative velocity (𝑣).

𝐹ℎ = 𝑏(ℎ)𝑣

(5.5)

The corresponding drag transfer function has the form

𝐻ℎ (𝜔) = 2𝜋𝑖𝜔𝑏(ℎ)

(5.6)
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The drag factor at contact, 𝑏(0), can be estimated by measuring 𝐻ℎ (𝜔) at different distances,
computing 𝑏(ℎ) with equation (5.6) and extrapolating to ℎ = 0 with the scaled spherical model
(5.7).

𝑏(ℎ) =

6𝜋𝜂𝑎𝑒𝑓𝑓 2

(5.7)

ℎ+ℎ𝑒𝑓𝑓

Where 𝜂 is the liquid viscosity, 𝑎𝑒𝑓𝑓 is the effective radius of the cantilever, and ℎ𝑒𝑓𝑓 is the
effective height of the tip. Alcaraz et al suggest that drag artifact in contact microrheological
measurements under low Reynolds numbers (Re < 1) can be accurately estimated by 𝑏(0) (274).

5.1.3. Oscillation on cell

The model essentially relies on Hertzian contact mechanics assuming pyramidal indenter
geometry

𝐹=

3𝐸tan(𝜃) 2
𝛿
4(1−𝜐2 )

(5.8)

Where 𝐸 and 𝜐 are the Young’s modulus and the Poisson’s ration of a cell, respectively. 𝜐 is
assumed to be 0.5 for a RBC. According to Alcaraz et al (161, 274) the complex modulus is given
by

𝐺 ∗ (𝜔) = 𝐺 ′ (𝜔) + 𝑖𝐺 ″ (𝜔) =

1−𝜐
𝐹(𝜔)
3𝛿0 tan(𝜃) 𝛿(𝜔)

(5.9)

After correction for the hydrodynamic drag acting on the oscillating cantilever, the expression for
the complex shear modulus becomes
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𝐺 ∗ (𝜔) = 𝐺 ′ (𝜔) + 𝑖𝐺 ″ (𝜔) =

1−𝜐
𝐹(𝜔)
(
3𝛿0 tan(𝜃) 𝛿(𝜔)

− 𝑖𝜔𝑏(ℎ0 ))

(5.10)

The ration between 𝐹(𝜔) and 𝛿(𝜔) can be calculated from the measured amplitudes 𝐴𝐹 (𝜔) and
𝐴𝛿 (𝜔) and phases 𝜑𝐹 (𝜔) and 𝜑𝛿 (𝜔) with the correction of the system lag

𝐹(𝜔)
𝛿(𝜔)

𝐴 (𝜔)

= 𝐴𝐹(𝜔) 𝑒 𝑖[𝜑𝐹(𝜔)−𝜑𝛿(𝜔)−𝜑𝑙𝑎𝑔]

(5.11)

𝛿

We applied sinusoidal oscillation loadings to WT-, SCT-, and SS-RBCs. The results showed that
the storage modulus (elastic modulus) 𝐺 ′ was insensitive to frequencies 10-100 Hz, but increased
rapidly at frequencies 100-200 Hz; the loss modulus (frictional modulus) 𝐺 ″ increased
substantially with the increasing frequency at 5-200 Hz, see Figure 5.6, 5.7, and 5.8. In addition,
the storage modulus was larger than the loss modulus for WT- and SCT-RBCs at frequencies 5200 Hz, for SS-RBCs at frequencies 5-80 Hz. Distinctively, for SS-RBCs, 𝐺 ″ crossovered 𝐺 ′ at
the frequency of ~80 Hz; above 80 Hz the loss modulus was larger than the storage modulus.
The domination shift from 𝐺 ′ to 𝐺 ″ suggest that SS-RBCs show a more solid-like behavior at low
frequencies; but behave more like a viscous liquid when exposed to high frequency loadings.
While WT-RBCs and SCT-RBCs exhibited a predominantly elastic behavior at the whole
frequency range tested (5-200 Hz).
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Figure 5.6. WT-RBC G’ & G’’ as a function of the oscillation frequency. Results are
shown as mean ± SD, including a total of 6 cells.

Figure 5.7. SCT-RBC G’ & G’’ as a function of the oscillation frequency. Results are
shown as mean ± SD, including a total of 6 cells.
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Figure 5.8. SS-RBC G’ & G’’ as a function of the oscillation frequency. Results are
shown as mean ± SD, including a total of 6 cells.

5.2. RBC adhesion comparison between normoxic and hypoxic conditions

In SCD, RBCs expose to low oxygen condition could be a critical point triggering the detrimental
changes in the cell deformability and adhesion properties. Better understanding of the RBC
mechanical and adhesive properties under hypoxic conditions is important in order to reverse the
harmful change or at least reduce the damage. We applied a non-toxic oxygen scavenger agent,
sodium sulfite, to normal RBCs and measured the cell stiffness and the single cell adhesion to
αvβ3 integrin.

A normal blood sample was obtained from freshly drawn, heparin-anticoagulated venous blood
collected by Research Blood Components, LLC. Whole blood was centrifuged at 500 × g for 5
min at 4˚C to separate the RBCs. The plasma and buffy coat were extracted and discarded. Then,
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the remaining RBCs were washed three times with Alsever’s solution and stored at 4˚C for up to
7 days.

5.2.1. Stiffness measurement under normoxic and hypoxic conditions

RBCs were seeded in a glass-bottom petri dish (Ted Pella, Redding, CA) that was pretreated with
1 mg/mL poly-L-lysine solution (Sigma-Aldrich) for 15 min at room temperature. Under these
conditions, RBCs adhered slightly to the substrate while they maintained their biconcave shape.
The hypoxic condition was obtained by adding freshly prepared sodium sulfite solution (in PBS,
1M) to the petri dish.

The stiffness measurements were carried out in contact mode AFM using silicon nitride
cantilevers with a nominal spring constant of 0.03 N/m (Bruker Nano, Camarillo, CA). The tip
height was between 2.5 and 8 mm and the nominal tip radius was 20 nm. Exact values for the
cantilever spring constants were obtained via a thermal noise based method implemented by the
manufacturer and were used in all calculations. Measurements were performed in PBS (normoxic)
or 1M sodium sulfite solution in PBS (hypoxic) at 25°C. The force curves were generated at a
loading rate of 24,000 pN/s, and for each state, normoxic and hypoxic, 250 measurements were
collected from a total of 5 cells.

The results showed that deoxygenated RBCs were significantly softer than oxygenated RBCs
(Figure 5.9). Young’s modulus values (mean ± SEM) of oxygenated and deoxygenated RBCs
were 5.68 ± 0.28 kPa, 2.038 ± 0.071 kPa (p<0.0001), respectively. Significance was determined
using the nonparametric Mann-Whitney test. The results were considered significant if p<0.05.
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Figure 5.9. Box-and-whisker plot showing Young’s modulus of WT-RBCs under
normoxic and hypoxic conditions. Data are shown as the median with minimum and
maximum whiskers, and the mean is denoted as a dot. Significance between conditions is
denoted as * such that p < 0.0001. The n on the x-axis indicates the total number of mature
WT-RBCs analyzed in each group, obtained from the same human subject.

5.2.2. Single cell adhesion measurement under normoxic and hypoxic conditions

Glass petri dishes (Ted Pella, Redding, CA) were divided using a hydrophobic PAP pen (Sigma
Aldrich, St. Louis, MO) to separate RBCs from the αvβ3 surface (Figure 5.10). Half of the glass
surface was silanized with 2% v/v APTES in acetone for 10min, rinsed with deionized (DI) water,
treated with 0.5% v/v glutaraldehyde (solution in DI water) for 30 min, rinsed, incubated in 100
μg/mL αvβ3 (solution in PBS) for 30min, rinsed, and incubated in 100 μg/mL BSA for 1 min.

Tipless silicon nitride AFM cantilevers (NanoWorld, Neuchâtel, Switzerland) were soaked in
acetone for 5min, UV irradiated for 15 min, incubated overnight in 0.5 mg/mL biotin-BSA at 37 ˚C,
rinsed with PBS and treated with 1% glutaraldehyde for 30s, rinsed, incubated in 0.5mg/mL
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streptavidin for 10 min, rinsed, and incubated in 0.5 mg/mL biotinylated Con A for 10 min at 25
˚C.

Cells were allowed to bind weakly to the non-functionalized region of the glass substrate via 10min
incubation at 37°C followed by rinsing with PBS solution, thus allowing for cantilever engagement
with a chosen RBC. Single cells were captured by positioning the Con A functionalized cantilever
above the cell center (Figure 5.10) and gently lowering onto the cell for ~30s. The cell was then
lifted from the surface and allowed to establish firm adhesion to the cantilever before relocation
to the αvβ3-functionalized region of the dish.

Figure 5.10. Schematic of a SCFS experiment between RBCs and the αvβ3-functionalized
substrate. (A) A tipless Con A-functionalized AFM cantilever capturing a RBC. (B) Relocating
the attached RBC to the αvβ3-functionalized substrate. (C) A real RBC attached to a tipless
cantilever.
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Each SCFS measuring session involved testing a single RBC attached to a previously calibrated
cantilever for 110 approach/retraction cycles on an αvβ3-functionalized glass substrate.
Measurements were performed in PBS (normoxic) or 1M sodium sulfite solution in PBS (hypoxic)
at 25°C. For each state, normoxic and hypoxic, 550 measurements were collected from a total of
5 cells.

The results showed that deoxygenated RBCs were significantly more adhesive to the αvβ3functionalized substrate than oxygenated RBCs did (Figure 5.11). Detachment forces (mean ±
SEM) for oxygenated and deoxygenated RBCs were 55.06 ± 0.98 pN, 66.28 ± 1.43 pN (p<0.0001).
Significance was determined using the nonparametric Mann-Whitney test. The results were
considered significant if p<0.05.

Figure 5.11. Box-and-whisker plot showing the detachment forces obtained for WTRBCs retracting from the αvβ3 substrate under normoxic and hypoxic conditions. Data
are shown as the median with minimum and maximum whiskers, and the mean is denoted as
a dot. Significance between conditions is denoted as * such that p < 0.0001. The n on the xaxis indicates the total number of mature WT-RBCs analyzed in each group, obtained from
the same human subject.
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Chapter 6. Epilogue

Sickle cell disease (SCD) is one of the first genetic diseases ever diagnosed. It is a really painful
and debilitating chronical disease that can cause shortness of breath, fatigue, delayed growth and
development in children, yellowing of the eyes and skin, and more serious complications, such
as pulmonary hypertension and multiple organ damages including brain damage from stroke. In
SCD, a single point mutation occurs in the β-globin gene and lead to production of abnormal
hemoglobin HbS which in deoxygenated conditions polymerizes to form stiff filaments. This is
severely detrimental to the RBC biophysical functions. It not only causes distortion to the shape
of the RBC from biconcave to "sickled", but also makes the RBC stiffer, more viscous, and show
higher adhesion than normal (wild-type) WT-RBCs to other RBCs, platelets, leukocytes, and to
the endothelium. Abnormal SS-RBC adhesion leads to delayed microvascular passage of
deoxygenated RBCs inducing sickling and entrapment of RBCs triggering vaso-occlusive
episodes (VOEs) which is the pathophysiologic hallmark of SCD. Anti-adhesive agents have
shown positive impacts in pre-clinical research and clinical trials and are potential candidates for
alleviating pain and managing SCD crisis onset.

Work from others and us (74, 171, 172) has demonstrated that increased SS-RBC adhesion is
due to higher density of functional adhesion receptors on the RBC membrane. RBC receptor
activation depends upon intracellular signaling pathways (5) that can be activated by extracellular
stimuli. One such pathway is cAMP-PKA which can be activated by epinephrine, a catecholamine,
which binds to G protein-coupled receptor and activates the downstream signaling (74, 172, 173).
It has been shown that the cAMP-PKA pathway directly regulates the activation of the basal cell
adhesion molecule/Lutheran (BCAM/Lu) on the RBC surface (172, 174). In addition, studies using
a variety of adhesion assays including micropipetting and perfusion chambers revealed that SSRBCs adhere to endothelial cells (170, 175), inducing endothelial injury and inflammation likely
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contributing to vaso-occlusive events (65, 170, 176-178). Zennadi et al. (66) further showed that
intercellular adhesion molecule-4 (ICAM-4) was the primary receptor mediating the adhesion of
SS-RBCs to endothelial cells and that the ligand for the ICAM-4 receptor was the endothelial αvβ3
integrin (66, 179, 180). They also identified that epinephrine can stimulate the activation of ICAM4 at least partially via the cAMP-PKA dependent signaling pathway. Here, RBC adhesion was
studied in detail in terms of ICAM-4 activation at single molecule level. We investigated the effects
of the cAMP-PKA dependent pathway modulation on (i) the binding between ICAM-4 and αvβ3
and (ii) the expression of active ICAM-4 receptors on the membrane of both WT-RBCs and SSRBCs. We also investigated whether AKAPs play a role in ICAM-4 activation. We implemented
single-molecule force spectroscopy (SMFS) by using an atomic force microscope (AFM) which
allows for the detection of single functional receptors on cells and at the same time for the
measurement of the unbinding force between a receptor and the corresponding ligand (172, 192198). It also allows detection of variations in the collective frequency (CF) of active ICAM-4
receptors on the RBC membrane. We used several biochemical reagents that affect the cAMPPKA pathway and investigated if the AKAP-PKA complex regulates ICAM-4 activation. In addition,
we used confocal microscopy to corroborate our AFM results. The findings suggest that activation
of ICAM-4 adhesion receptors is regulated by the cAMP-PKA signaling pathway and more
importantly can be mediated via AKAPs.

Previous research has shown that the adrenergic system and the renin-angiotensin system are
interrelated, moreover, in human embryonic kidney (HEK) cells, mouse cardiomyocytes, and
COS-7 cell lines there is a direct interaction and cross-regulation between β-Adrenergic receptor
(β-AR) and angiotensin II type 1 receptor (AT1R). It was found that a single receptor antagonist
blocks downstream signaling of both β-AR and AT1R. We made a hypothesis that this cross-talk
is active in RBCs. Specifically, valsartan, an AT1R blocker, may also have a profound effect on
attenuating ICAM-4 activation through receptor cross-talk. We employed SMFS to detect the
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ICAM-4 expression on WT-, SCT-, and SCD-RBCs and found that pretreatment of RBCs with
valsartan significantly hindered the activation of ICAM-4 receptors induced by epinephrine. The
findings of this work suggest that administration of valsartan offers a possible way to mitigate
vaso-occlusive episodes in SCD. In addition, patients with SCD are often prescribed renin–
angiotensin–aldosterone system (RAAS) blockers for management of sickle cell-related
nephropathy. Thus, valsartan administration may be a multi-beneficial remedy.

Clinical disparities were observed between African-American and white females in terms of
adverse events during chemotherapy, particularly among breast cancer patients, and overall
cancer survival. African-American women have more than 10% lower breast cancer survival than
white females, and this difference persisted over time. We studied blood samples from patients
with sickle cell trait (SCT), which is estimated to occur in 8-10% of African-Americans, in cancer
outcomes. We found that when chemotherapeutic agents interact with the RBC, they influence
ICAM-4 activation differently in white women with wild type hemoglobin than in African-American
women with wild type hemoglobin, and African-American women with SCT. This suggests race
and SCT carrying status may need to be deliberately considered in order to improve patient
outcomes during cancer chemotherapeutic treatment.

Further approaches to better understand RBC biophysics were expected to provide
comprehensive characteristics in terms of RBC rheology and adhesion. AFM can generate and
apply time-dependent loadings to RBC membrane with a precise control of the loading rate. The
complex ratio between the applied stress and the resulting strain, defined as complex modulus of
the material, can be obtained through analysis in the frequency domain. The real and imaginary
parts describe the elastic and viscous properties respectively, namely the viscoelasticity of a RBC.
We found that the storage modulus (elastic modulus) 𝐺 ′ was insensitive to frequencies 10-100
Hz, but increased rapidly at frequencies 100-200 Hz. The loss modulus (frictional modulus) 𝐺 ″
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increased appreciably with the increasing frequency at 5-200 Hz. In addition, for WT-RBCs and
SCT-RBCs, the whole frequency domain 5-200 Hz was dominated by 𝐺 ′ suggesting cells
exhibited a predominantly elastic behavior. In contrast, there was a cross point between 𝐺 ′ and
𝐺 ″ for SS-RBCs at the frequency of ~80 Hz, below 80 Hz 𝐺 ′ > 𝐺 ″ , above 80 Hz 𝐺 ″ > 𝐺 ′ ,
suggesting that SS-RBCs show a more solid-like behavior at low frequencies; but behave more
like a viscous liquid when exposed to high frequency loadings. To better understand the molecular
mechanisms underlying cell microrheology in health and disease, more comprehensive cell
structures need to be characterized, including the plasma membrane, the cytoskeleton, and the
cytosol beneath the deformed cell surface.

In SCD, RBC deoxygenation most likely would cause changes in the cell motility and adherence,
leading to painful vaso-occlusive crisis and sometimes severe complications. In order to reverse
the detrimental changes, better understanding of the mechanical and adhesion properties of the
RBC in hypoxic conditions is intensively needed. We applied a non-toxic oxygen scavenger agent,
sodium sulfite, to WT-RBCs and measured the cell stiffness and the single cell adhesion using
SMFS and SCFS respectively. We found that deoxygenated WT-RBCs were significantly softer
and more adhesive to αvβ3 than oxygenated WT-RBCs did. The same measurement could be
extended to SS-RBCs. Better understanding the mechanical and adhesion properties of the SSRBCs in hypoxia conditions may be helpful for improving SCD crisis management and impacting
patient outcomes. More accurate oxygen scavenging and real-time oxygen level measurement
along with the SMFS and SCFS techniques could further enhance the accuracy of the
measurement. Oxygen sensing technique, such as fluorescence quenching, may be a good
choice since it works in a non-destructive manner.
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